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A B S T R A C T
Background
The World Health Organization (WHO) in 2015 stated atovaquone-proguanil can be used in travellers, and is an option in malaria-endemic
areas in combination with artesunate, as an alternative treatment where first-line artemisinin-based combination therapy (ACT) is not
available or eNective. This review is an update of a Cochrane Review undertaken in 2005.
Objectives
To assess the eNicacy and safety of atovaquone-proguanil (alone and in combination with artemisinin drugs) versus other antimalarial
drugs for treating uncomplicated Plasmodium falciparum malaria in adults and children.
Search methods
The date of the last trial search was 30 January 2020. Search locations for published trials included the Cochrane Infectious Diseases Group
Specialized Register, CENTRAL, MEDLINE, Embase, and LILACS. To include recently published and unpublished trials, we also searched
ClinicalTrials.gov, the metaRegister of Controlled Trials and the WHO International Clinical Trials Registry Platform Search Portal.
Selection criteria
Randomized controlled trials (RCTs) reporting eNicacy and safety data for atovaquone-proguanil or atovaquone-proguanil with a partner
drug compared with at least one other antimalarial drug for treating uncomplicated Plasmodium falciparum infection.
Data collection and analysis
For this update, two review authors re-extracted data and assessed certainty of evidence. We meta-analyzed data to calculate risk ratios
(RRs) with 95% confidence intervals (CI) for treatment failures between comparisons, and for safety outcomes between and across
comparisons. Outcome measures include unadjusted treatment failures and polymerase chain reaction (PCR)-adjusted treatment failures.
PCR adjustment diNerentiates new infection from recrudescent infection.
Main results
Seventeen RCTs met our inclusion criteria providing 4763 adults and children from Africa, South-America, and South-East Asia. Eight trials
reported PCR-adjusted data to distinguish between new and recrudescent infection during the follow-up period. In this abstract, we report
only the comparisons against the three WHO-recommended antimalarials which were included within these trials.
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There were two comparisons with artemether-lumefantrine, one trial from 2008 in Ethiopia with 60 participants had two failures with
atovaquone-proguanil compared to none with artemether-lumefantrine (PCR-adjusted treatment failures at day 28). A second trial from
2012 in Colombia with 208 participants had one failure in each arm (PCR-adjusted treatment failures at day 42).
There was only one comparison with artesunate-amodiaquine from a 2014 trial conducted in Cameroon. There were six failures with
atovaquone-proguanil at day 28 and two with artesunate-amodiaquine (PCR-adjusted treatment failures at day 28: 9.4% with atovaquone-
proguanil compared to 2.9% with artesunate-amodiaquine; RR 3.19, 95% CI 0.67 to 15.22; 1 RCT, 132 participants; low-certainty evidence),
although there was a similar number of PCR-unadjusted treatment failures (9 (14.1%) with atovaquone-proguanil and 8 (11.8%) with
artesunate-amodiaquine; RR 1.20, 95% CI 0.49 to 2.91; 1 RCT, 132 participants; low-certainty evidence).
There were two comparisons with artesunate-mefloquine from a 2012 trial in Colombia and a 2002 trial in Thailand where there are
high levels of multi-resistant malaria. There were similar numbers of PCR-adjusted treatment failures between groups at day 42 (2.7%
with atovaquone-proguanil compared to 2.4% with artesunate-mefloquine; RR 1.15, 95% CI 0.57 to 2.34; 2 RCTs, 1168 participants;
high-certainty evidence). There were also similar PCR-unadjusted treatment failures between groups (5.3% with atovaquone-proguanil
compared to 6.6% with artesunate-mefloquine; RR 0.8, 95% CI 0.5 to 1.3; 1 RCT, 1063 participants; low-certainty evidence).
When atovaquone-proguanil was combined with artesunate, there were fewer treatment failures with and without PCR-adjustment at day
28 (PCR-adjusted treatment failures at day 28: 2.16% with atovaquone-proguanil compared to no failures with artesunate-atovaquone-
proguanil; RR 5.14, 95% CI 0.61 to 43.52; 2 RCTs, 375 participants, low-certainty evidence) and day 42 (PCR-adjusted treatment failures
at day 42: 3.82% with atovaquone-proguanil compared to 2.05% with artesunate-atovaquone-proguanil (RR 1.84, 95% CI 0.95 to 3.56; 2
RCTs, 1258 participants, moderate-certainty evidence). In the 2002 trial in Thailand, there were fewer treatment failures in the artesunate-
atovaquone-proguanil group compared to the atovaquone-proguanil group at day 42 with PCR-adjustment.
Whilst there were some small diNerences in which adverse events were more frequent in the atovaquone-proguanil groups compared to
comparator drugs, there were no recurrent associations to suggest that atovaquone-proguanil is strongly associated with any specific
adverse event.
Authors' conclusions
Atovaquone-proguanil was eNective against uncomplicated P falciparum malaria, although in some instances treatment failure rates were
between 5% and 10%. The addition of artesunate to atovaquone-proguanil may reduce treatment failure rates. Artesunate-atovaquone-
proguanil and the development of parasite resistance may represent an area for further research.
P L A I N   L A N G U A G E   S U M M A R Y
What are the benefits and risks of atovaquone-proguanil for treating uncomplicated malaria caused by the Plasmodium falciparum
parasite?
What is the aim of this review?
The most common, and most serious, type of malaria is caused by Plasmodium falciparum. In its mild (uncomplicated) form, the symptoms
are fever, headaches, muscle pain, and vomiting. The disease can become severe and life-threatening if it is not treated soon enough or
with the right medicines.
This review aimed to find out whether atovaquone-proguanil is eNective and safe for treating uncomplicated cases of P falciparum malaria.
We aimed to achieve this by comparing the results of studies that had compared atovaquone-proguanil to other malaria treatments.
Key messages
Atovaquone-proguanil is as eNective for treating uncomplicated Plasmodium falciparum malaria as artesunate-mefloquine. It may be less
eNective than artemether-lumefantrine, artesunate-amodiaquine, and artesunate-atovaquone-proguanil, though more robust evidence
is needed to confirm this. Side eNects seem similar with atovaquone-proguanil.
What was studied in this review?
The World Health Organization (WHO) recommends treating uncomplicated malaria with oral (by mouth) artemisinin-based combination
medicines (called ACTs).
ACTs are not always available worldwide and, in some places, Plasmodium falciparum is becoming resistant to recommended treatments
(the medicines stop working). We looked at the evidence about the benefits and harms of combinations of medicines that are not
artemisinin-based, but contain atovaquone-proguanil. This is an oral treatment commonly used by people from non-malaria areas to
prevent them catching malaria when they travel to malaria areas. We wanted to find out whether it works as well for treating uncomplicated
Plasmodium falciparum malaria as ACTs and other malaria treatments.
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We searched for randomized controlled trials (clinical studies where people are randomly put into one of two or more treatment groups)
that compared atovaquone-proguanil against other malaria treatments. These studies provide the most robust evidence about the eNects
of a treatment. We compared results, summarized the evidence, and rated our confidence in the evidence.
What are the main results of the review?
We found 17 studies involving 4763 adults and children in Africa, South America, and South East Asia. People were followed for 28 days
to one year.
FiJeen studies compared atovaquone-proguanil against 12 diNerent antimalarial treatments (ACTs in five studies; other therapies that
combined several medicines in two studies; single medicines in nine studies).
Five studies compared atovaquone-proguanil plus another medicine (artesunate or chloroquine) against atovaquone-proguanil alone
(three studies); atovaquone-proguanil plus a diNerent medicine (one study); a combination of therapies that did not include atovaquone-
proguanil (one study); or single medicines (two studies).
In 15 studies, the researchers and people who were treated knew which medicines participants received. Pharmaceutical companies
funded 10 studies.
Atovaquone-proguanil against ACTs recommended by the WHO
Atovaquone-proguanil may work less well to clear Plasmodium falciparum parasites from the blood or prevent them from returning
(treatment success) than artemether-lumefantrine (rates of success compared 28 and 42 days aJer treatment; one study). However this
evidence was based on one small study.
Atovaquone-proguanil may work as well as, or less well than, artesunate-amodiaquine depending on whether new infections appearing
aJer the start of treatment were counted or not (rates of success compared three and 28 days aJer treatment; one study). However this
evidence was based on one small study of children aged under five years.
When new infections aJer the start of treatment were excluded, there is strong evidence of little to no diNerence in treatment success
between atovaquone-proguanil and artesunate-mefloquine aJer 42 days (two studies). When new infections were counted, atovaquone-
proguanil may be better than artesunate-mefloquine, but this evidence was based on the imprecise results of one study.
Atovaquone-proguanil against atovaquone-proguanil plus artesunate
Compared to atovaquone-proguanil plus artesunate, atovaquone-proguanil may be less successful at treating uncomplicated malaria aJer
three and 28 days, however this evidence is based on the results of two small studies. It is probably less successful at treating uncomplicated
malaria aJer 42 days (two studies).
Side e$ects
Studies reported several side eNects, such as nausea and vomiting, or headaches. Overall, they were similar between groups.
How-up-to date is this review?
The evidence is current to 30 January 2020.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Atovaquone-proguanil compared to artemether-lumefantrine for treating uncomplicated Plasmodium falciparum malaria
Atovaquone-proguanil compared to artemether-lumefantrine for treating uncomplicated Plasmodium falciparum malaria
Patient or population: children and adults















Total failure day 28
PCR-adjusted






Compared to AL, AV+PG may have more PCR-adjust-
ed treatment failures at day 28.
Total failure day 42
PCR-unadjusted






Compared to AL, AV+PG may have more PCR-unad-
justed treatment failures at day 28.
Anticipated absolute effects† (95%
CI)
Risk with AL Risk with AV+PG
Total failure day 42
PCR-adjusted








Compared to AL, AV+PG may have more PCR-adjust-
ed treatment failures at day 42.
*We presented study event rates rather than anticipated absolute effects as there were no events in the AL group.
† The risk in the intervention group (and its 95% confidence interval) was based on the assumed risk in the comparison group and the relative effect of the intervention
(and its 95% CI).
AL: artemether-lumefantrine; AV+PG: atovaquone-proguanil; CI: confidence interval; PCR: polymerase chain reaction; RCT: randomized controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.




















































































































































































Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded two levels for serious imprecision. Small number of participants and wide confidence intervals.
bWe noted that indirectness was present as only one study contributed to each outcome. However, as there were higher treatment failures consistently with atovaquone-proguanil
compared to artemether-lumefantrine between the two studies, we did not downgrade to beyond low certainty.
 
 
Summary of findings 2.   Atovaquone-proguanil compared to artesunate-amodiaquine for treating uncomplicated Plasmodium falciparum malaria
Atovaquone-proguanil compared to artesunate-amodiaquine for treating uncomplicated Plasmodium falciparum malaria




























Compared to AS+AQ, AV+PG may have more PCR-ad-












There may be little or no difference in PCR-adjusted
failures at day 28 between AS+AQ and AV+PG.
Study event rates†
With AS+AQ With AV+PG
Early treatment
failure







Compared to AS+AQ, AV+PG may have more early
treatment failures.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
†We presented study event rates rather than anticipated absolute effects as there were no events in the AL group for two of the outcomes.
AS+AQ: artesunate-amodiaquine; AV+PG: atovaquone-proguanil; CI: confidence interval; PCR: polymerase chain reaction; RCT: randomized controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence




















































































































































































Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded one level for indirectness. Trial of children aged under five years only.
bDowngraded one level for imprecision. Low numbers of events.
 
 
Summary of findings 3.   Atovaquone-proguanil compared to artesunate-mefloquine for treating uncomplicated Plasmodium falciparum malaria
Atovaquone-proguanil compared to artesunate-mefloquine for treating uncomplicated Plasmodium falciparum malaria
Patient or population: children and adults
Setting: Colombia and Thailand
Intervention: AV+PG
Comparison: AS+MQ
















Total failure day 42
PCR-adjusted








There was little to no difference in PCR-adjusted fail-
ures at day 42 between AS+MQ and AV+PG.
Total failure day 42
PCR-unadjusted








Compared to AS+MQ, AV+PG may have fewer PCR-
unadjusted treatments at day 42.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
AS+MQ: artesunate-mefloquine; AV+PG: atovaquone-proguanil; CI: confidence interval; PCR: polymerase chain reaction; RCT: randomized controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.




















































































































































































aDowngraded two levels for imprecision. The confidence interval crossed the line of no eNect, and the eNect size was small.
 
 
Summary of findings 4.   Atovaquone-proguanil compared to artesunate-atovaquone-proguanil for treating uncomplicated Plasmodium falciparum
malaria
Atovaquone-proguanil compared to artesunate-atovaquone-proguanil for health problem or population
Patient or population: children and adults



















Total failure day 28
PCR-adjusted






Compared to AS+AV+PG, AV+PG may have more PCR-adjusted
treatment failures at day 28.
Total failure day 28
PCR-unadjusted






Compared to AS+AV+PG, AV+PG may have more PCR-unadjust-







Total failure [day 42
PCR-adjusted









Compared to AS+AV+PG, AV+PG probably leads to more PCR-
adjusted treatment failures at day 42.
Total failure day 42
PCR-unadjusted









Compared to AS+AV+PG, AV+PG probably leads to more PCR-
unadjusted treatment failures at day 42.
Early treatment
failure



























































































































































































* We presented study event rates rather than anticipated absolute effects as there were no events in the AL group.
† The risk in the intervention group (and its 95% confidence interval) was based on the assumed risk in the comparison group and the relative effect of the intervention
(and its 95% CI).
AS+AV+PG: artesunate-atovaquone-proguanil; AV+PG: atovaquone-proguanil; CI: confidence interval; PCR: polymerase chain reaction; RCT: randomized controlled trial;
RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded two levels for imprecision. Wide confidence interval that crossed the line of no eNect.
bDowngraded one level for indirectness. Evidence came from one study in children only.
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B A C K G R O U N D
Description of the condition
Plasmodium falciparum is the most important of all species of
malaria. In 2016, it was responsible for 99% of malaria cases in the
World Health Organization (WHO) African region, and 66% in the
South-East Asia region (WHO 2017).
Uncomplicated malaria is defined by the absence of clinical
features that define severe malaria in the presence of
an asexual P falciparum parasitaemia (WHO 2015). Severe
malaria is defined as a P falciparum parasitaemia with one
or more of: impaired consciousness, prostration, multiple
convulsions, acidosis, hypoglycaemia, severe malarial anaemia,
renal impairment, jaundice, pulmonary oedema, significant
bleeding, shock, or a parasitaemia greater than 10%.
The first-line treatment for uncomplicated P falciparum malaria
is artemisinin-based combination therapy (ACT) (WHO 2015). The
artemisinin component rapidly clears parasites from the blood. It
is active against some sexual stages of the parasite, particularly
immature gametocytes. This property helps reduce post-treatment
malaria transmission. The partner drug is longer acting and
protects the artemisinin component from resistance. Those with
longer half-lives also provide post-treatment prophylaxis against
reinfection.
Artemisinin resistance has emerged in South East Asia; initially
in Western Cambodia (Noedl 2008), but has since become
prevalent in Laos, Myanmar, Thailand, and Vietnam (the Greater
Mekong subregion). Genetic mutations associated with artemisinin
resistance in these areas have also been detected at significant
prevalence (greater than 5%) in Guyana, Papua New Guinea, and
Rwanda, although the clinical significance is uncertain (WHO 2019).
Historically, chloroquine-resistant malaria emerged in the Greater
Mekong subregion, an area of low transmission. It has since spread
through Asia and Africa. Further spread of artemisinin resistance
could lead to higher mortality from malaria (Lubell 2014).
Description of the intervention
Atovaquone-proguanil is commonly used to prevent malaria when
travelling (ACMP 2017). It is a 'causal' prophylactic agent, meaning
that it inhibits liver stage development of malaria. This means that
it needs to be taken only for one week aJer travel to endemic areas
(rather than four weeks, as for doxycycline or mefloquine).
The WHO also supports use of atovaquone-proguanil outside
malaria-endemic areas and in combination with artesunate and
primaquine as an alternative treatment where first-line ACT is
not available or eNective (WHO 2015). It has been used in areas
where there are high rates of treatment failure associated with
artemisinins (WHO 2012), and as such it is important to understand
how it compares to ACTs and other antimalarials. The high cost
of atovaquone-proguanil has limited its use for treatment, and a
public-private partnership to provide the drug for free was short-
lived due to concerns about poor use of resources (Oyediran
2002). While atovaquone-proguanil was previously only available
as Malarone, it is now available oN-licence in generic formulations.
How the intervention might work
Atovaquone selectively inhibits electron transport in the malarial
cytochrome b complex. Proguanil hydrochloride mainly acts via
the metabolite cycloguanil, a dihydrofolate reductase inhibitor.
Proguanil's main eNect is to potentiate atovaquone, rather than
having direct antimalarial activity. As such, although it has
two components, atovaquone-proguanil is not a combination
equivalent to ACT, in which two antimalarial drugs with diNerent
modes of action, are combined.
Resistance to atovaquone is a potential barrier to its widespread
use. Resistance predominantly emerges rapidly via single point
mutations in the malarial cytochrome b gene (Blasco 2017). Animal
studies suggest that resistance may be non-transmissible as the
mutation significantly reduces parasite fitness (Goodman 2016).
Therefore, it is likely that resistance usually originates in the
parasite from de novo mutations, rather than being spread between
mosquitoes and humans.
Atovaquone is poorly absorbed, though proguanil is rapidly
absorbed from the gastrointestinal tract. The elimination half-
life of atovaquone is about two days to three days in adults,
and of proguanil is 12 hours to 15 hours in adults (WHO 2015).
These elimination half-lives are longer than artemisinins, similar
to lumefantrine and sulfadoxine-pyrimethamine, but shorter than
mefloquine or piperaquine.
Why it is important to do this review
This review is an update of a Cochrane Review first published
in 2005 (Osei-Akoto 2005). The previous review included 10
randomized controlled trials (RCTs) and concluded that there
was some evidence that atovaquone-proguanil was superior
to chloroquine, mefloquine, and amodiaquine, but that there
was insuNicient data for other comparisons. The authors
recommended larger trials comparing atovaquone-proguanil with
new combination therapies.
A 2017 non-Cochrane systematic review aimed to estimate eNicacy
of atovaquone-proguanil for treatment of uncomplicated malaria
(including, but not limited to P falciparum) (Staines 2017). This
included one study (Bustos 1999), which the original authors of
this Cochrane Review excluded due to protocol amendments.
Staines 2017 also excluded one study included in the previous
Cochrane Review (Van Vugt 2002), but the reason for this was
unclear. The analysis combined RCTs and observational studies,
and used single-arm weighted means to estimate atovaquone-
proguanil treatment eNicacy. The authors used the outcome of
'treatment success at day 28', but it was unclear how this outcome
was defined. Within their discussion, the authors state that "meta-
analysis suggests that atovaquone-proguanil treatment success is
equivalent to the use of ACT". Given the strength of this conclusion,
we considered it would be useful to re-evaluate the evidence using
updated Cochrane methodology.
Since the last update in 2005, the Cochrane Review process has
evolved. An updated review will benefit from GRADE methodology,
which will allow greater clarity for the assessment of the certainty
of evidence. Inclusion of 'Summary of findings' tables will help to
frame conclusions with clear indications to the reader regarding the
certainty of evidence presented.
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This remains an important and relevant area, particularly in the
context of evolving antimalarial drug resistance.
O B J E C T I V E S
To assess the eNicacy and safety of atovaquone-proguanil
(alone and in combination with artemisinin drugs) versus
other antimalarial drugs for treating uncomplicated Plasmodium
falciparum malaria in adults and children.
M E T H O D S




Children and adults with uncomplicated P falciparum malaria




Atovaquone-proguanil, alone or in combination with other
antimalarials.
Control
Other antimalarial drugs, alone or in combination with other
antimalarials.
Types of outcome measures
We collected data on both primary and secondary outcome
measures.
Primary outcomes
• Total treatment failure at day 28 (polymerase chain reaction
(PCR)-adjusted and unadjusted).
• Total treatment failure at day 42 (PCR-adjusted and unadjusted).
We based these primary outcome measures on WHO
recommendations (WHO 2003; WHO 2009), which advise a 28-
day follow-up to capture most failures, and 42-day follow-up
to capture failures for drugs with a longer elimination half-
life (mefloquine and piperaquine). PCR adjustment diNerentiates
recrudescent infections from new infections during follow-up but
may misclassify. Unadjusted treatment failure helps indicate the
post-treatment prophylactic eNect of partner drugs. Including both
measures helps inform policy makers, and these outcomes are also
consistent with previous Cochrane Reviews.
We did not use adequate clinical and parasitological response
(ACPR) as this is defined as absence of failure and is, therefore,
duplication.
Secondary outcomes
• Early treatment failure (WHO 2009):
* danger signs or severe malaria on days one, two, or three in
the presence of parasitaemia;
* parasitaemia on day two higher than on day zero, irrespective
of axillary temperature;
* parasitaemia on day three with axillary temperature 37.5 °C
or greater; and
* parasitaemia on day three 25% or greater of count on day 0.
It is important to include data for parasitaemia on day three as this
is both part of the standardized definition for treatment response
used for all levels of malaria transmission, and it is regarded as an
indirect marker of artemisinin resistance (WHO 2009; WHO 2011).
Adverse events
• Serious adverse events (including death, life-threatening
events, hospitalization, and disability).
• Adverse events leading to withdrawal from the trial.
• Other adverse events.
Search methods for identification of studies
We aimed to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress). We searched for relevant trials on 10 January 2018, 14
January 2019 and 30 January 2020.
Electronic searches
The authors of the review and the Cochrane Infectious Disease
Group information specialist Vittoria Lutje (VL) attempted to
identify all relevant trials. We searched the following databases
using the search terms and strategy described in Appendix 1:
• Cochrane Infectious Diseases Group (CIDG) Specialized Register;




We searched ClinicalTrials.gov, the metaRegister of Controlled
Trials and the WHO International Clinical Trials Registry Platform
Search Portal for ongoing or recently completed trials. The date of
the last search was 30 January 2020.
Searching other resources
To identify additional published, unpublished, and ongoing
studies, we checked the reference lists of all studies identified.
The original authors of this review circulated a list of identified
studies to individual researchers working in the field and to the
drug manufacturer to help identify additional trials and provide
information on ongoing trials (Osei-Akoto 2005). We did not do this
and did not search conference abstracts or proceedings because
improved trial methods and search methodology means that
relevant trials are more readily found through electronic databases.
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Data collection and analysis
Selection of studies
For this update, two review authors (AB and PH) independently
screened newly identified articles by title and abstract to assess if
they met the inclusion criteria. There were no disagreements. We
documented the reason for excluding trials in the Characteristics
of excluded studies table. We presented an adapted PRISMA flow
diagram for review updates, following standard guidance (Mohor
2009; Stovold 2014).
Data extraction and management
Due to changes in the primary and secondary outcomes of the
review compared to the previous version and to ensure consistency,
two review authors (AB and PH) independently re-extracted all data
using a standardized form.
Unadjusted total failure rate day 28 and day 42
We extracted the following data and summed it to form the
numerator.
• Early treatment failure.
• Late clinical failure.
• Late parasitological failure.
We extracted the following data and subtracted it from the number
of participants randomized. This formed the denominator.
• Those found not to be fulfilling inclusion criteria aJer
randomization.
• Those voluntarily withdrawing consent.
• Those lost to follow-up.
• Those violating protocol, including (but not limited to) missed or
vomited doses, those failing to complete treatment, and those
taking additional antimalarials.
Polymerase chain reaction-adjusted total failure rate day 28 and
day 42
We extracted the following data and summed it to form the
numerator.
• Early treatment failure due to PCR-confirmed recrudescence.
• Late clinical failure due to PCR-confirmed recrudescence.
• Late parasitological failure due to PCR-confirmed
recrudescence.
We extracted the following data and subtracted it from the number
of participants randomized. This formed the denominator.
• Those with indeterminate PCR results.
• Those with missing PCR results.
• Those with PCR-confirmed new infections.
• Those found not to be fulfilling inclusion criteria aJer
randomization.
• Those voluntarily withdrawing consent.
• Those lost to follow-up.
• Those violating protocol, including (but not limited to) missed or
vomited doses, those failing to complete treatment, and those
taking additional antimalarials.
Adverse events
We extracted the number of people who had been reported
as experiencing an adverse event to form the numerator. The
denominator was formed from the number of people who had
received at least one dose of the study drug, unless otherwise
stated. We used the Medical Dictionary for Regulatory Activities to
search for a 'higher level term' to group adverse events together
and allow comparison between studies using diNerent descriptors
for similar and related symptoms (MedDRA 2018). Where a study
reported multiple adverse events that had a common MedDRA
term, we only included the most common adverse event to avoid
double counting. Where more than one 'higher level term' was
given for a symptom, we consistently applied the term that we
considered most appropriate, and used footnotes in the forest plots
to describe original terms where a 'higher level term' might be
considered ambiguous.
Comment on eicacy denominators
This approach was based on standard WHO approaches for
assessing and monitoring antimalarial drug eNicacy (WHO 2003;
WHO 2009). We adopted this approach within our review to ensure
consistency with the WHO approach, and the analysis method used
in previous Cochrane systematic reviews of malaria treatment. We
recognize that this method excludes a high number of randomized
participants from the denominator for the final eNicacy outcome. In
order to restore integrity of randomization, we had planned
to conduct a series of sensitivity analyses (as described in Table 1),
but, given the small number of trials included for each comparison,
we did not pursue this as it was unlikely to alter conclusions.
Assessment of risk of bias in included studies
Two review authors (AB and PH) independently used the 'Risk of
bias' tool developed by Cochrane to assess and identify bias in
included studies (Higgins 2017). We categorized six domains as
being high risk, low risk, or unclear risk, which are displayed in the
Characteristics of included studies table.
Measures of treatment e=ect
We calculated risk ratios (RRs) with 95% confidence intervals (CIs)
for dichotomous data.
Unit of analysis issues
There were no unit of analysis issues.
Dealing with missing data
We contacted trial authors to clarify ambiguous data and to add
missing data that would be helpful for this review. We excluded
some data because it was not interpretable. In particular, we
encountered diNiculties interpreting participant dropout rates to
form the denominator for treatment failures. We explained any
deviations from our protocol in footnotes presented with the forest
plots.
Assessment of heterogeneity
We visually inspected forest plots for overlapping CIs as an indicator
of clinical heterogeneity. We also used a Chi2 test with a significance
level of P < 0.1 or an I2 statistic greater than 75% (or both) as an
indication of substantial heterogeneity.
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Assessment of reporting biases
We did not produce a funnel plot to investigate publication bias
because this review contained a large number of comparator drugs
rather than reviews that have compared AV+PG against the same
control drug.
Data synthesis
We analyzed the data using Review Manager 5 (Review Manager
2014). We planned to use a fixed-eNect model for meta-analysis
if we deemed there to be no substantial heterogeneity, and a
random-eNects model if we identified substantial heterogeneity.
Because we found no substantial heterogeneity, we used fixed-
eNect modelling throughout.
Subgroup analysis and investigation of heterogeneity
Within our protocol, we intended to explore heterogeneity using
subgroup analysis, but there were too few trials in each comparison
to yield meaningful results.
Sensitivity analysis
Within our protocol, we intended to conduct a sensitivity analysis
adding excluded groups back into the analysis using stepwise
methods. Given the small number of trials included for each
comparison, we did not pursue this, but the planned analysis is
presented in Table 1 for reference.
Summary of findings and assessment of the certainty of the
evidence
We assessed the certainty of the evidence using the GRADE
approach (Schünemann 2013). We appraised the certainty of
evidence in relation to the following criteria.
• Study design.




• Other considerations (including publication bias).
We used GRADEpro 2015 to create 'Summary of findings' tables for
outcomes related to treatment failure.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies tables.
Results of the search
The updated literature search on 30 January 2020 identified 59
references. Two studies were duplicates and we excluded a further
45 studies aJer title and abstract screening. We assessed 12 full-
text articles for eligibility of which seven met the inclusion criteria.
We screened the 10 trials included in a previous review; all met
the inclusion criteria giving a total of 17 studies (see Characteristics
of included studies and Characteristics of excluded studies tables;
and the PRISMA study flow diagram (Figure 1)). Our search initially
identified Wojnarski 2019 as an abstract report, but the full results
have since been published.
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Figure 1.   PRISMA diagram.
 
We contacted authors of 15 studies to request additional
information. Eight authors replied (De Alencar 1997; Llanos-
Cuentas 2001; Borrmann 2003; McGready 2005; Gurkov 2008;
Carrasquilla 2012; Laufer 2012; Wojnarski 2019). We did not receive
replies from the authors of seven studies (RadloN 1996; Anabwani
1999; Looareesuwan 1999; Mulenga 1999; Van Vugt 2002; Mulenga
2006; Tahar 2014). We did not need to contact the remaining
authors.
Included studies
We identified 17 studies with 4763 participants; 2839 from trials
included in the original review (RadloN 1996; De Alencar 1997;
Anabwani 1999; Looareesuwan 1999; Mulenga 1999; Bouchaud
2000; Llanos-Cuentas 2001; Van Vugt 2002; Borrmann 2003; Giao
2004), and 1924 participants from newly included trials (McGready
2005; Mulenga 2006; Gurkov 2008; Carrasquilla 2012; Laufer 2012;
Tahar 2014; Wojnarski 2019).
The studies compared atovaquone-proguanil to 12 diNerent
antimalarial drugs, including ACTs and non-combination therapies.
Table 2 gives a summary of the comparisons made between studies.
Table 3 summarizes the outcomes reported by the diNerent studies.
We presented the trials with the dates of data collection, global
region, and a range of failure rates for atovaquone-proguanil and
comparator drugs in Table 4 so that it is easy to compare the overall
findings between publication date, trial dates, and global regions.
Studies comparing atovaquone-proguanil to WHO-
recommended artemisinin-based combination therapy
Four studies compared atovaquone-proguanil to WHO-
recommended ACTs (Van Vugt 2002; Gurkov 2008; Carrasquilla
2012; Tahar 2014). These studies included 2296 participants.
Carrasquilla 2012 included adults and children older than 12 years
in South America. Gurkov 2008 included adults and children older
than five years in Africa. Tahar 2014 included children aged six
months to five years in Africa. Van Vugt 2002 included adults and
children older than two years in Thailand. The four studies used
weight-based dosing for atovaquone-proguanil.
Other comparisons
Studies comparing atovaquone-proguanil to artesunate-atovaquone-
proguanil
Three studies compared atovaquone-proguanil to artesunate-
atovaquone-proguanil (Van Vugt 2002; Tahar 2014; Wojnarski 2019).
These studies included 2139 participants. Tahar 2014 included
children aged six months to five years in Africa. Van Vugt 2002
included adults and children older than two years in Thailand.
Wojnarski 2019 included adults in Cambodia.
Studies comparing atovaquone-proguanil to other combinations or to
monotherapy
Three studies compared atovaquone-proguanil to combination
therapies that are not recommended by WHO (De Alencar
1997; Giao 2004; Laufer 2012). One study compared artesunate-
atovaquone-proguanil to quinine (McGready 2005). Ten studies
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compared atovaquone-proguanil to monotherapies (RadloN 1996;
Looareesuwan 1999; Mulenga 1999; Bouchaud 2000; Llanos-
Cuentas 2001; Borrmann 2003; McGready 2005; Mulenga 2006;
Gurkov 2008; Laufer 2012).
Excluded studies
We excluded five studies. The reasons for their exclusion are listed
in the Characteristics of excluded studies table.
Risk of bias in included studies
See Figure 2 for 'Risk of bias' summary and Characteristics of
included studies table.
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Anabwani 1999 ? ? - ? + + ?
Borrmann 2003 + + - - - + ?
Bouchaud 2000 ? ? - ? + + ?
Carrasquilla 2012 ? ? - + + + ?
De Alencar 1997 + + - - + + +
Giao 2004 + + - ? + + ?
Gurkov 2008 + ? - + + + +
Laufer 2012 + ? - ? + + +
Llanos-Cuentas 2001 + ? - ? + + +
Looareesuwan 1999 ? ? - ? + + ?
McGready 2005 + + - ? + + ?
Mulenga 1999 ? ? - ? + + ?
Mulenga 2006 + ? + ? - + ?
Radloff 1996 + ? - ? + + ?
Tahar 2014 ? ? ? ? + ? +
Van Vugt 2002 ? + - ? + ? +
Wojnarski 2019 + + - ? + + +
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Allocation
Nine trials described adequate sequence generation (RadloN
1996; De Alencar 1997; Borrmann 2003; Giao 2004; McGready
2005; Mulenga 2006; Gurkov 2008; Laufer 2012; Wojnarski 2019).
Correspondence with a study author confirmed the use of
a computer-generated randomization code for a further study
(Llanos-Cuentas 2001). It was unclear how the allocation sequence
had been generated in the remaining seven studies.
Five trials described methodology for allocation concealment (Van
Vugt 2002; Borrmann 2003; Giao 2004; McGready 2005; Wojnarski
2019); one further study was confirmed through correspondence to
have used sealed envelopes (De Alencar 1997). The remaining trials
were at unclear risk.
Blinding
Only one trial blinded participants and personnel (Mulenga 2006).
Tahar 2014 mentioned the use of blinding in the trial registration,
but did not describe how this was performed. The remaining 15
trials were described as 'open-label', and, as such, we regarded
them at high risk of performance bias, and of unclear risk of
detection bias; we considered that the laboratory staN assessing
the primary outcomes were unlikely to have been aware of
treatment allocations.
Incomplete outcome data
We judged Mulenga 2006 at high risk of attrition bias given a
relatively high attrition rate that may be suNicient to introduce
clinically relevant bias (approximately 75% followed up at day 28).
Similarly, we concluded that Borrmann 2003 was at high risk of
attrition bias as there was diNerential attrition between study arms;
in one arm there was 22% loss to follow-up, but only 8% loss to
follow-up in the other. The remaining trials had either low rates
of attrition, or moderate rates of attrition which were distributed
evenly between arms; therefore, we judged these to have low risk
of bias.
Selective reporting
One trial was retrospectively registered (Tahar 2014), another trial
reported on an outcome (gametocyte carriage) not listed in the
methodology (Van Vugt 2002). The authors of Wojnarski 2019
initially declined to share unpublished data, though their trial was
later published in June 2019. There was no evidence of reporting
bias in the other trials.
Other potential sources of bias
Ten studies were directly funded by pharmaceutical companies; for
seven of these studies, we were unable to identify assurances of
author independence from conflicts of interest and have, therefore,
listed the risk of bias as unclear. Two studies received tablet
donations from pharmaceutical companies but gave assurance of
author independence. Of the 10 studies funded by pharmaceutical
companies, five had the same senior author. Other sources of
funding were national and charitable foundations, as well as the
armed forces.
E=ects of interventions
See: Summary of findings 1 Atovaquone-proguanil compared to
artemether-lumefantrine for treating uncomplicated Plasmodium
falciparum malaria; Summary of findings 2 Atovaquone-
proguanil compared to artesunate-amodiaquine for treating
uncomplicated Plasmodium falciparum malaria; Summary of
findings 3 Atovaquone-proguanil compared to artesunate-
mefloquine for treating uncomplicated Plasmodium falciparum
malaria; Summary of findings 4 Atovaquone-proguanil compared
to artesunate-atovaquone-proguanil for treating uncomplicated
Plasmodium falciparum malaria
Abbreviations
In this analysis section, we used standard abbreviations for the
antimalarial drugs (Appendix 2).
Crude treatment failure rates
Table 5 reports treatment failure rates at day 28 and day 42.
We have not weighted or pooled these, but presented them
for completeness. Three studies reported PCR-adjusted treatment
failure rates at day 28, and, in two of these, the treatment failure
rate for AV+PG was greater than 5% (Gurkov 2008; Tahar 2014).
Three studies reported PCR-adjusted treatment failure rates at day
42, and, in one of these, the treatment failure rate for AV+PG was
greater than 5% (Wojnarski 2019). In none of the studies did PCR-
adjusted treatment failure rate at day 28 or day 42 for AV+PG exceed
10%.
Studies comparing atovaquone-proguanil to WHO-
recommended artemisinin-based combination therapy
Comparison 1. Atovaquone-proguanil versus artemether-
lumefantrine
Two studies compared AV+PG versus AL (Gurkov 2008; Carrasquilla
2012). See Summary of findings 1.
We were only able to reliably extract data for one study reporting
PCR-adjusted treatment failures at day 28 (Gurkov 2008). There
were fewer PCR-adjusted treatment failures at day 28 following
treatment with AL compared to AV+PG, but the CIs were very wide
and crossed the line of no eNect (RR 5.00, 95% CI 0.25 to 99.95; 1
RCT, 60 participants; Analysis 1.1).
Only one study reported PCR-adjusted treatment failures at day 42
(Carrasquilla 2012). There was one PCR-adjusted treatment failure
at day 42 following treatment with both AL and AV+PG. The CIs
crossed the line of no eNect (RR 3.00, 95% CI 0.19 to 47.12; 1 RCT,
208 participants, Analysis 1.2).
There were fewer PCR-unadjusted treatment failures at day 42
following treatment with AL compared to AV+PG, but the CIs were
wide and crossed the line of no eNect (RR 5.00, 95% CI 0.25 to
99.95; 1 RCT, 60 participants, Analysis 1.3). Neither trial report early
treatment failure, nor PCR-unadjusted failures at day 28.
Adverse events
There were no serious adverse events or adverse events leading
to withdrawal in either study contributing to this comparison.
Headaches and nausea and vomiting were reported more
frequently in participants receiving AV+PG compared to AL
(headaches: RR 2.54, 95% CI 1.17 to 5.51; nausea and vomiting: RR
10.00, 95% CI 2.73 to 36.60; 2 RCTs, 272 participants; Analysis 1.4).
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Comparison 2. Atovaquone-proguanil versus artesunate-
amodiaquine
One study contributed data to this comparison (Tahar 2014). See
Summary of findings 2.
There were more PCR-adjusted treatment failures at day 28
following treatment with AV+PG compared to AS+AQ, but the CIs
crossed the line of no eNect (RR 3.19, 95% CI 0.67 to 15.22; 1 RCT,
132 participants; Analysis 2.1).
There were similar numbers of PCR-unadjusted treatment failures
at day 28 between treatments (RR 1.20, 95% CI 0.49 to 2.91; 1 RCT;
132 participants; Analysis 2.2).
The study did not report outcomes beyond day 28.
There were more early treatment failures following treatment with
AV+PG compared to AS+AQ, but the CIs were wide and crossed
the line of no eNect (RR 13.80, 95% CI 0.79 to 240.11; 1 RCT, 132
participants; Analysis 2.3).
Adverse events
There were no serious adverse events. The authors reported one
adverse event leading to withdrawal in the AV+PG group, but it
is not clear what this event was (RR 3.04, 95% CI 0.13 to 73.43; 1
RCT, 139 participants; Analysis 2.4). They report that other adverse
events occurred but did not report these individually or by study
group.
Comparison 3. Atovaquone-proguanil versus artesunate-
mefloquine
Two studies contributed data to this comparison (Van Vugt 2002;
Carrasquilla 2012). See Summary of findings 3.
There were similar numbers of PCR-adjusted treatment failure at
day 42 between treatments (RR 1.15, 95% CI 0.57 to 2.34; 2 RCTs,
1168 participants; Analysis 3.1).
We were only able to reliably extract data for one study reporting
PCR-unadjusted treatment failures at day 42 (Van Vugt 2002). In this
study, there were fewer PCR-unadjusted treatment failures in the
AV+PG group compared to the AS+MQ group, but the confidence
intervals crossed the line of no eNect (RR 0.80, 95% CI 0.50 to 1.30;
1 RCT, 1063 participants; Analysis 3.2).
Adverse events
There were three serious adverse events in groups receiving AS
+MQ, compared to one serious adverse event in groups receiving AV
+PG. The CIs crossed the line of no eNect (RR 0.64, 95% CI 0.10 to
4.22; 2 RCTs, 1275 participants; Analysis 3.3).
Some adverse events were more common in the AS+MQ arm.
Significant adverse events included febrile disorders (RR 6.00, 95%
CI 1.13 to 31.83; 1 RCT, 212 participants; Analysis 3.3) and headaches
(RR 3.00, 95% CI 1.10 to 8.16; 1 RCT, 212 participants; Analysis 3.3).
Nausea and vomiting was more common in the AV+PG group (RR
0.63, 95% CI 0.44 to 0.89; 2 RCTs, 896 participants, Analysis 3.3). The
RR for other adverse events had wide CIs that crossed the line of no
eNect.
Other comparisons
Studies comparing atovaquone-proguanil to artesunate-
atovaquone-proguanil
Three studies compared AV+PG versus AS+AV+PG (Van Vugt 2002;
Tahar 2014; Wojnarski 2019). Tahar 2014 reported early treatment
failures and day 28 data, but not day 42 data. Van Vugt 2002
reported day 42 data, but we could not extract day 28 treatment
failures from the study, although the authors showed these on a
figure. Wojnarski 2019 reported early treatment failures as well as
day 28 and day 42 data with PCR adjustment, though we could not
reliably extract PCR-unadjusted data. See Summary of findings 4.
Both PCR-adjusted treatment failures and PCR-unadjusted
treatment failures occurred more frequently at day 28 with AV+PG
compared to AS+AV+PG, but the CIs were wide and crossed the line
of no eNect (PCR-adjusted: RR 5.14, 95% CI 0.61 to 43.52; 2 RCTs, 375
participants; Analysis 4.1; PCR-unadjusted: RR 15.48, 95% CI 0.90 to
267.27; 1 RCT, 187 participants; Analysis 4.2).
There were more PCR-adjusted treatment failures at day 42
following treatment with AV+PG compared to AS+AV+PG (RR 1.84,
95% CI 0.95 to 3.56; 2 RCTs, 1258 participants; Analysis 4.3). There
were more PCR-unadjusted treatment failures at day 42 following
treatment with AS+AV compared to AS+AV+PG, although the CIs
crossed the line of no eNect (RR 1.56, 95% CI 0.88 to 2.79; 1 RCT, 1063
participants; Analysis 4.4).
There were more early treatment failures with AV+PG compared to
AS+AV+PG, but the CIs crossed the line of no eNect (RR 5.11, 95% CI
0.25 to 104.94; 2 RCTs, 395 participants; Analysis 4.5).
Adverse events
Van Vugt 2002 presented combined adverse events for two
interventions and we were unable to obtain the separate data. We
were able to extract some data showing that nausea and vomiting
occurred more oJen in the AS+AV+PG group compared to the AV
+PG group. This was significant at the 95% confidence level (RR
0.52, 95% CI 0.34 to 0.80; 1 RCT, 664 participants; Analysis 4.6). Tahar
2014 did not report on adverse events and Wojnarski 2019 reported
one serious adverse event in each arm, neither of which the study
authors considered was likely related to treatment.
Studies comparing atovaquone-proguanil to other combinations
or to monotherapy
We presented these comparisons in a narrative summary table
(Table 6).
Other comparisons
McGready 2005 compared AS+AV+PG to quinine. There were more
PCR-adjusted and unadjusted treatment failures in the QN group at
all time points (Analysis 13.1; Analysis 13.2; Analysis 13.3; Analysis
13.4; Analysis 13.5). There were more hearing problems in the QN
group (Analysis 13.6).
Laufer 2012 compared CQ+AV+PG to CQ monotherapy; there were
no treatment failures in either arm (Analysis 14.1; Analysis 14.2).
Laufer 2012 also compared CQ+AV+PG to CQ+AS. There was
one PCR-adjusted treatment failure, and one PCR-unadjusted
treatment failure at day 28 in the CQ+AS arm compared to no
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treatment failures in the CQ+AV+PG arm. CIs crossed the line of no
eNect (Analysis 15.1; Analysis 15.2).
Laufer 2012 also compared CQ+AV+PG to CQ+AZ. There was one
PCR-unadjusted failure in the CQ-AZ arm. CIs crossed the line of no
eNect (Analysis 16.1; Analysis 16.2).
None of the studies in which a drug was combined with AV+PG to
form an intervention reported on drug-drug interactions between
AP and the partner drug.
Atovaquone-proguanil versus WHO-recommended
artemisinin-based combination therapies
We performed a supplementary analysis comparing AV+PG to
pooled results for WHO-recommended ACTs to allow for easier
comparison with the findings of another systematic review
(Analysis 18.1; Analysis 18.3) (Staines 2017).
Atovaquone-proguanil versus all other antimalarials for
adverse events
We compared adverse events across all studies. Adverse events
leading to withdrawal from the studies occurred more commonly
in the AV+PG groups. The only other adverse event that appeared
to be observed more frequently in AV+PG compared to other
antimalarials was abnormal liver function tests, but data for this
came from a single study (Looareesuwan 1999; RR 2.50, 95% CI 1.02
to 6.16; 1 RCT, 182 participants; Analysis 17.23).
D I S C U S S I O N
Summary of main results
For most studies, failure rates were less than 5%. However, two
studies reported crude PCR-adjusted failure rates greater than 5%
at day 28 for atovaquone-proguanil (Gurkov 2008; Tahar 2014), and
one study reported crude PCR-adjusted failure rates greater than
5% at day 42 (Wojnarski 2019).
Compared to artemether-lumefantrine, atovaquone-proguanil
may have more PCR-adjusted treatment failures at day 28 and 42
(day 28: RR 5.0, 95% CI 0.25 to 99.95; 1 RCT, 60 participants; low-
certainty evidence; day 42: RR 3.0, 95% CI 0.19 to 47.12; 1 RCT, 208
participants; low-certainty evidence). Compared to artemether-
lumefantrine, atovaquone-proguanil may also have more PCR-
unadjusted treatment failures at day 28 (RR 5.00, 95% CI 0.25 to
99.95; 1 RCT, 60 participants; low-certainty evidence). See Summary
of findings 1.
Compared to artesunate-amodiaquine, atovaquone-proguanil
may have more PCR-adjusted failures at day 28 (RR 3.19, 95% CI 0.67
to 15.22; 1 RCT, 132 participants; low-certainty evidence), but there
may be little or no diNerence in PCR-unadjusted failures at day 28
(RR 1.20, 95% CI 0.49 to 2.91; 1 RCT, 132 participants; low-certainty
evidence). Of concern, the study that assessed this comparison
reported a high number of early treatment failures (Tahar 2014). Of
note, this study included only at children aged six months to five
years. See Summary of findings 2.
Compared to artesunate-mefloquine, there was little or no
diNerence in PCR-adjusted failures at day 42 (RR 1.15, 95% CI 0.57 to
2.34; 2 RCTs, 1168 participants; high-certainty evidence). Compared
to artesunate-mefloquine, atovaquone-proguanil may have fewer
PCR-unadjusted treatments at day 42 (RR 0.8, 95% CI 0.5 to 1.3; 1
RCT, 1063 participants; low-certainty evidence). See Summary of
findings 3.
Addition of artesunate to atovaquone-proguanil appears to yield
lower failure rates compared to atovaquone-proguanil alone at all
time points, although certainty of evidence was low to moderate.
See Summary of findings 4.
Compared to monotherapies, atovaquone-proguanil performed
better than quinine, mefloquine, amodiaquine, and
chloroquine. For comparisons to other combination
therapies, the performance of atovaquone-proguanil was
similar to that of dihydroartemisinin-piperaquine-trimethoprim-
primaquine, quinine-tetracycline, sulfadoxine-pyrimethamine,
and halofantrine.
When atovaquone-proguanil was compared against all other
antimalarials, there were more participants with serious adverse
events that led to their withdrawal from the study in the
atovaquone-proguanil groups. One study that contributed to this
diNerence was Mulenga 2006, in which there were six deaths in the
atovaquone-proguanil group. These included three children who
deteriorated within 24 hours of receiving atovaquone-proguanil;
their deaths were likely to have been from malaria, as well
as three children who died of causes likely to be unrelated to
malaria, according to the authors. The only other adverse event
that appeared to be observed more frequently with atovaquone-
proguanil compared to other antimalarials was abnormal liver
function tests, but data for this came from a single study
(Looareesuwan 1999; RR 2.50, 95% CI 1.02 to 6.16; 1 RCT, 182
participants; Analysis 17.23), and was not found across other
studies. Therefore, this can be regarded as low certainty. The
addition of artesunate to atovaquone-proguanil led to increased
nausea and vomiting in the trial that included adults (Van Vugt
2002).
Overall completeness and applicability of evidence
This review included 4250 participants of varying ages and genders
across a wide geographical reach including Africa, South America,
and South East Asia. However, the number of comparisons and
outcomes reported were broad and include antimalarials that are
not currently recommended by the WHO. This limited the extent
to which we could meaningfully pool and compare the data in this
review.
Only seven of the included trials reported PCR-adjusted failure
rates. Of those trials comparing atovaquone-proguanil to WHO-
recommended ACTs, the trials did not consistently report early
treatment failures or outcomes at day 28 and day 42. Day 42
failure rates are important in capturing treatment failures that may
occur when treating people with antimalarials with a long half-life
(Stepniewska 2004), and because some mutations are specifically
associated with late parasite recrudescence (Staines 2017).
There was extensive heterogeneity in the reporting of adverse
events across trials; in some instances, adverse events were
mentioned as being 'not present'.
Evidence of drug eNicacy and related adverse events are important
factors in determining the role of antimalarial agents, but they
must be considered in a wider context when contemplating
whether atovaquone-proguanil can be adopted more readily
on a large scale. One of the greatest barriers to antimalarial
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use is undoubtedly the development of drug resistance; this
has been well documented in atovaquone-proguanil. Several
strategies for delaying the emergence of resistance to atovaquone-
proguanil have been suggested and include increasing the dose
of atovaquone-proguanil to maintain higher blood concentrations,
particularly early in infection, combining atovaquone-proguanil
with other antimalarials, and targeting treatment at areas where
there are low levels of mutant genes (Cottrell 2014). As suggested by
our findings, the addition of artesunate to atovaquone-proguanil
may result in greater eNicacy, but the evidence is low certainty and
the eNect of this on the development of resistance has not been
studied.
Certainty of the evidence
We assessed the certainty of the evidence in this review using
the GRADE approach and presented it in Summary of findings 1,
Summary of findings 2, Summary of findings 3, and Summary of
findings 4. In almost all outcomes, we downgraded the certainty
of evidence due to imprecision. This was because trials were
small and there were few events. For most outcomes, we also
downgraded the certainty of evidence due to indirectness, as each
outcome was oJen informed by a single trial in a single population.
Potential biases in the review process
As we did not encounter standardized outcome reporting, in some
instances we made inferences during the data extraction process
which we reported in footnotes in the analysis tables. Where there
was doubt, we were conservative in our decisions so as not to
overestimate the eNect size. In some trials, authors reported failure
rates as percentages or represented them graphically in figures
but did not report numbers of events or totals. This meant that
it was not possible to extract data from these studies. To attempt
to mitigate this, we contacted authors for clarification, but did not
receive a reply in all instances.
We chose to use MedDRA 2018 to standardize adverse events
terminology to allow comparison across trials. This has led to some
reduction in detail, and subjectivity of their interpretation may lead
to misclassification. However, we feel that standardization of these
terms allows for a more meaningful overview and comparison
of the adverse events between the diNerent treatments. For the
comparison of adverse events with atovaquone-proguanil to all
other antimalarials (Analysis 17.1 to Analysis 17.35), where a trial
had more than one comparator drug, we chose the comparator
drug that was associated with the most number of events for the
specific symptom experienced so as not to include participants
in the atovaquone-proguanil arm more than once in the analysis
(indicated in individual footnotes).
Agreements and disagreements with other studies or
reviews
Staines 2017 expressed the overall eNicacy rate of atovaquone-
proguanil at day 28 based on study sizes and heterogeneity, and
reported eNicacy of 89% in 'intention-to-treat' analyses of RCTs.
They concluded that this is a "reassuringly acceptable level of
eNicacy". We did not pool treatment failure rates across studies, but
have presented a narrative overview in Table 5, including day 42
PCR-adjusted results.
Staines 2017 presented a forest plot in which compared
atovaquone-proguanil to other ACTs at day 28. However, this
analysis included a combination treatment which is not WHO-
recommended (from Giao 2004), and did not refer to PCR-adjusted
results. On the basis of this, the authors concluded, "treatment
success is equivalent to the use of ACT". To reconcile this diNerence,
we performed supplementary analyses (Analysis 18.1; Analysis
18.2; Analysis 18.3; Analysis 18.4). For each outcome, atovaquone-
proguanil performed less well than WHO-recommended ACT,
except at day 48 for PCR-unadjusted failure rates. The CIs crossed
the line of no eNect in each of these, except for PCR-adjusted failures
at day 42.
The overall conclusion of Staines 2017 is that atovaquone-
proguanil therapy is comparable in eNicacy to ACT when treating
uncomplicated malaria. Given the uncertainty of evidence, our
analysis cannot support this conclusion.
In the previous version of this review (Osei-Akoto 2005), the original
authors pooled the participants randomized to atovaquone-
proguanil from Llanos-Cuentas 2001. We felt it was more
appropriate to split the participants into two groups as was done in
the trial. This has led to a diNerent reported RR, but has not altered
the conclusion.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Atovaquone-proguanil is eNicacious against uncomplicated
Plasmodium falciparum malaria, but treatment failure exceeded 5%
in two studies, the level at which the WHO recommends avoiding
adoption of antimalarial medicines in country programmes.
Although it is eNicacious, we cannot conclude with certainty that it
has comparable clinical eNicacy to WHO-recommended ACTs.
The addition of artesunate to atovaquone-proguanil may reduce
the treatment failure rates. Artesunate-atovaquone-proguanil is
not currently available in coformulation, therefore it is unlikely
that this combination could be readily adopted in clinical settings.
Potential resistance to atovaquone-proguanil is likely to be a barrier
to its widespread uptake, but there may be strategies to delay the
emergence of resistance that require further exploration.
Implications for research
There remains uncertainty about the eNicacy of atovaquone-
proguanil compared to WHO-recommended artemisinin-based
combination therapies (ACT). However, given the strength of expert
opinion favouring the importance of ACT therapy, and a risk of
emerging resistance, it is unlikely there is suNicient uncertainty to
justify further primary research comparing atovaquone-proguanil
to WHO-recommended ACTs.
The combination of artesunate with atovaquone-proguanil may
represent a promising treatment strategy, and should be compared
directly to first-line ACTs, particularly in geographical areas of
resistance.
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Methods Randomized controlled trial
Duration: 6 months; June 1994 to November 1994
Participants Children with uncomplicated P falciparum malaria
Number: 168
Inclusion criteria: aged 3–12 years; fever; tolerate oral therapy; weight > 10 kg
Exclusion criteria: severe malaria; QTc interval > 0.44 seconds; mixed infections
Diagnosis: parasitaemia 1000–200,000 parasites/μL
Interventions • Atovaquone-proguanil (atovaquone 60 mg/kg + proguanil 24 mg/kg for 3 days)
• Halofantrine (24 mg/kg for 12 hours)
Outcomes • 28-day cure rate (parasite clearance within 7 days without recrudescence during the 28-day follow-up
period)
• Parasite clearance time (initiation of treatment to smear negative for asexual parasites)a
• Fever clearance time (initiation of treatment until temperature < 37.2 °C and remained < 37.2 °C for
24 hours)a
• Adverse events
aNot assessed in quantitative synthesis in this review.
Notes Follow-up: 28 days
Countries (codes): Kenya (KEN)
Setting: district hospital
Malaria endemicity: high transmission (> 1 case per 1000 population)
Source of funding: grant from Glaxo Wellcome
Additional correspondence: we emailed the authors on 11 July 2018 but did not receive a reply.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Random assignment of study number".
Allocation concealment
(selection bias)





High risk Open label.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Open label.
Incomplete outcome data
(attrition bias)
Low risk 164/168 (97%) participants evaluable.
Anabwani 1999  (Continued)
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Low risk No reporting bias detected.





Methods Randomized controlled trial
Duration: 2 years; January 1999 to December 2000
Participants Children with uncomplicated P falciparum malaria
Number: 200
Inclusion criteria: weight 5–11 kg (age not in inclusion criteria)
Exclusion criteria: antimalarials within previous 7 days; underlying severe disease; concomitant infec-
tion; mixed infection; allergy to study drugs; severe malaria
Diagnosis: parasitaemia 1000–200,000 parasites/μL
Interventions • Atovaquone-proguanil (atovaquone 62.5 mg + proguanil 25 mg for 3 days)
• Amodiaquine (amodiaquine chlorohydrate 10 mg/kg of a 1% suspension once daily for 3 days)
Outcomes • 28-day cure rate (absence of early or late treatment failure, no PCR adjustment)
• Parasite clearance time (treatment initiation until temperature < 37.5 °C and remained at 37.5 °C for
> 24 hour)a
• Fever clearance time (treatment initiation until first negative blood smear)a
• Adverse events (including haematological/biochemical)
aNot assessed in quantitative synthesis in this review.
Notes Follow-up: 28 days
Countries (codes): Gabon (GAB)
Setting: hospital
Malaria endemicity: high transmission (> 1 case per 1000 population)
Source of funding: GlaxoSmithKline
Additional correspondence: we received email correspondence from S Borrmann on 18 January 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Blocks of 10 and sequentially assigned to groups.
Borrmann 2003 
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Allocation concealment
(selection bias)






Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Open-label; no reported blinding of outcome assessors (confirmed by S Bor-




High risk 92/100 participants in atovaquone/proguanil group with day 28 data; 78/100
participants in amodiaquine group with day 28 data.
Selective reporting (re-
porting bias)
Low risk No reporting bias detected.
Other bias Unclear risk Email correspondence from S Borrmann: GlaxoSmithKline sponsored the
flights and accommodation for presentation of the study results. 1 author was





Methods Randomized controlled trial
Duration: 1 year; October 1994 to September 1995
Participants Adults and adolescents with imported uncomplicated P falciparum malaria
Number: 48
Inclusion criteria: aged > 16 years; imported malaria from short stay; non-immune
Exclusion criteria: severe malaria; QTc > 0.44 seconds; mixed infection; concomitant disease; inability
to take oral treatment; syncope; pregnancy/breastfeeding; weight < 40 kg; resided in an endemic area
for the previous year
Diagnosis: parasitaemia 1000–100,000 parasites/μL
Interventions • Atovaquone-proguanil (atovaquone 1 g + proguanil 400 mg as single daily dose for 3 days)
• Halofantrine (3 doses of 500 mg 6 hours apart)
Outcomes • Cure rate (defined as clinical and parasitological cure at day 7 without recrudescence at day 35)
• Parasite clearance time (treatment initiation until no asexual forms on thick films)a
• Fever clearance (treatment initiation until temperature of 37.2 ºC maintained for > 24 hours)a
• Adverse events (including QT elongation)
aNot assessed in quantitative synthesis in this review
Notes Follow-up: 35 days
Countries (codes): France (FRA)
Bouchaud 2000 
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Setting: not specified
Malaria endemicity: imported
Source of funding: Glaxo Wellcome Research and Development
Additional correspondence: we did not contact the authors.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described.
Allocation concealment
(selection bias)






Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk 85% of participants assessable.
Selective reporting (re-
porting bias)
Low risk No reporting bias detected.





Methods Randomized controlled trial
Duration: 1 year, 6 months; May 2007 to November 2008
Participants Adults and adolescents with P falciparum malaria or mixed infection
Number: 265
Inclusion criteria: aged > 12 year; history of fever
Exclusion criteria: severe malaria; multiple audiological exclusion criteria; pregnancy/breastfeeding;
abnormal cardiac function; prolonged QTc; taking drugs affecting cardiac function; serious underlying
disease; had received the following drugs within the previous 2 months: mefloquine, aminoglycoside
antibiotics, halofantrine, artemether-lumefantrine; received the following drugs within the previous 2
weeks: quinine, chloroquine, any other antimalarial drug, aspirin, loop diuretics, macrolide antibiotics
Diagnosis: parasite density 1000–100,000 parasites/μL blood
Carrasquilla 2012 
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Interventions Assigned in a 3:1:1 ratio
• Artemether-lumefantrine: 40 mg/240 mg (15–24 kg), 60 mg/360 mg (25–34 kg), or 80 mg/480 mg (≥ 35
kg) at 0, 8, 24, 36, 48, and 60 hours
• Atovaquone-proguanil: 250 mg/100 mg (11–20 kg), 500 mg/200 mg (21–30 kg) or 750 mg/300 mg (31–
40 kg), or 1000 mg/400 mg (> 40 kg) once daily
• Artesunate-mefloquine: artesunate 4 mg/kg/day + mefloquine 25 mg/kg (15 mg/kg on day 2 and 10
mg/kg on day 3)
Outcomes • Audiological outcomes: auditory brainstem response; pure-tone air conduction thresholda
• Adverse events
• PCR-corrected cure rates (reported at days 14, 28, and 42)
aNot assessed in quantitative synthesis in this review.
Notes Follow-up: 42 days
Countries (codes): Colombia (COL)
Setting: not specified
Malaria endemicity: low transmission (< 1 case per 1000 population-years). Colombia was entering con-
trol phase at time of the study
Source of funding: Novartis Pharma Ltd, Basel, Switzerland
Additional correspondence: we emailed 3 of the authors on 11 July 2018 for further information. We re-
ceived an initial reply but were unable to obtain the information needed.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described.
Allocation concealment
(selection bias)






Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk Quote: "1.5% patients discontinued the study prematurely".
Selective reporting (re-
porting bias)
Low risk No evidence to suggest selective reporting of efficacy outcomes.
Other bias Unclear risk 4 authors declared as employees of Novartis who funded the study; no assur-
ances given of independence in reporting.
Carrasquilla 2012  (Continued)
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Methods Randomized controlled trial
Duration: 10 months; April 1995 to January 1996
Participants Adult men with P falciparum malaria
Number: 175
Inclusion criteria: men; aged 18–65 years
Exclusion criteria: grossly abnormal laboratory results; refusal to be hospitalized for 28 days; inability
to tolerate study medication; missing study medication
Diagnosis: smear positive with parasitaemia 1000–100,000 parasites/μL
Interventions • Atovaquone-proguanil (atovaquone 1 g + proguanil 400 mg daily for 3 days)
• Quinine-tetracycline (quinine 600 mg 3 times a day + tetracycline 250 mg 4 times a day for 7 days)
Outcomes • 28-day cure rate (based on weekly thick smears)
• Parasite clearance time (time to last positive blood smear before 3 negatives)a
• Fever clearance time (time to last temperature of > 37.8 °C followed by 3 normal temperatures)a
• Adverse events
aNot assessed in quantitative synthesis in this review.
Notes Follow-up: 28 days
Countries (codes): Brazil (BRA)
Setting: National Health Foundation posts
Malaria endemicity: high transmission rate (as described in study)
Source of funding: Wellcome Diagnostics
Additional correspondence: we received email correspondence from F De Alencar on 12 July 2018.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Email correspondence: "The sequence was generated by statisticians of Well-
come Diagnostics and sent to the study sites".
Allocation concealment
(selection bias)
Low risk Email correspondence: "The sequence was kept locked in a cabin and was
conferred always by the same investigator at each enrolment as to define the





High risk Open label.
Blinding of outcome as-
sessment (detection bias)
High risk No blinding of outcome assessors.
De Alencar 1997 
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Low risk 154 analyzed/175 randomized (88%).
Selective reporting (re-
porting bias)
Low risk No evidence to suggest selective reporting.
Other bias Low risk Financial support from Wellcome Diagnostics.
Email correspondence: members of Wellcome did not have any participation
in the organization, execution, data collection, or data analysis, being restrict-






Methods Randomized controlled trial
Duration: 1 year, 4 months; April 2001 to August 2002
Participants Adults and adolescents with uncomplicated P falciparum malaria
Number: 165
Inclusion criteria: fever presenting at a primary care facility, aged > 16 years
Exclusion criteria: pregnancy/lactation; complicated malaria; inability to take oral medication; allergy
to study drugs; artemisinin within 24 hours; quinine within 12 hours; mefloquine/tetracycline/doxycy-
cline within 7 days
Diagnosis: parasitaemia > 1000 parasites/μL
Interventions • Atovaquone-proguanil (atovaquone 1 g + proguanil 400 mg once daily for 3 days
• Dihydroartemisinin-piperaquine-trimethoprim-primaquine (2 × dihydroartemisinin 32 mg + piper-
aquine phosphate 320 mg + trimethoprim 90 mg + primaquine phosphate 5 mg at time 0, 8, 24, and
48 hours)
Outcomes • 28-day cure rate (parasite clearance by day 7 without recrudescence up to day 28)
• Parasite clearance time (time 0 to the first of 3 negative blood smears)a
• Fever clearance time (time 0 to the first of 3 consecutive normal temperatures < 37.0 °C)a
• Adverse events
aNot assessed in quantitative synthesis in this review.
Notes Follow-up: all followed up for 28 days; 92 participants followed up for 56 days
Countries (codes): Vietnam (VNM)
Setting: primary healthcare facility
Malaria endemicity: high transmission (> 1 case per 1000 population)
Source of funding: quote: "tablets were kindly donated by Glaxo Wellcome UK".
Giao 2004 
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Additional correspondence: we did not contact the authors.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)










Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk 161 analyzed/165 randomized (98%).
Selective reporting (re-
porting bias)
Low risk No evidence to suggest selective reporting.
Other bias Unclear risk Quote: "Tablets donated"





Methods Randomized controlled trial
Duration: 5 months; April 2006 to August 2006
Participants Adults and children with uncomplicated P falciparum malaria
Number: 97
Inclusion criteria: aged > 5 years; temperature ≥ 37.5 °C or history of fever within 24 hours; tolerate oral
therapy; residence in study area, suitable for complete audio-vestibular testing
Exclusion criteria: known/suspected hearing deficits; antimalarials within 7 days; mixed infection; se-
vere malaria; severe underlying disease; concomitant disease masking assessment of response; allergy
to study medications; pregnancy
Diagnosis: thick and thin blood smears
Interventions • Artemether-lumefantrine (80 mg/480 mg (adults and children ≥ 35 kg bodyweight), at 0, 8, 24, 36, 48,
and 60 hours; dose adjusted by weight for younger children.
• Quinine (~ 8 mg/kg quinine base, 3 times daily for 7 days)
Gurkov 2008 
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• Atovaquone-proguanil (20 mg/8 mg/kg (children < 40 kg bodyweight) or 1000 mg/400 mg (adults and
children ≥ 40 kg bodyweight) per day for 3 days (3 doses)
Outcomes • Day 7 treatment failure
• Total treatment failure at day 28 (PCR adjusted and unadjusted)
• Tolerability and ototoxicity
Notes Follow-up: 90 days
Countries (codes): Ethiopia (ETH)
Setting: university hospital
Malaria endemicity: high transmission (> 1 case per 1000 population)
Source of funding: Friedrich-Baur-StiJung, Munich, Germany
Additional correspondence: we received email correspondence from T Löscher and N Berens-Riha on
13 July 2018.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated, stratified by gender and age.
Allocation concealment
(selection bias)





High risk Quote: "Open-label".
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk Day 28: 90 analyzed/97 randomized (92.7%).
Selective reporting (re-
porting bias)
Low risk Email correspondence: trial was registered before study at Ethiopian MOH. De-
layed registration at international registry due to 'communication problems'.





Methods Randomized controlled trial
Duration: 1 year, 7 months; February 2007 to August 2009
Participants Children with uncomplicated P falciparum malaria
Laufer 2012 
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Number: 640
Inclusion criteria: aged ≥ 6 months to 5 years; signs and symptoms consistent with malaria; weight ≥ 5
kg
Exclusion criteria: severe malaria; allergy to study drugs; medication with any antibiotic or antimalarial;
previous enrolment; raised ALT (> 5 × ULN); raised creatinine (> 3 × ULN); chronic disease; severe malnu-
trition, known HIV
Diagnosis: parasite density 2000–200,000 parasites/mL
Interventions • Chloroquine: 10 mg/kg on day 0 and 1, 5 mg/kg/day on day 2
• Chloroquine-artesunate (chloroquine: 10 mg/kg on day 0 and 1, 5 mg/kg/day on day 2 + artesunate:
4 mg/kg once a day for 3 days)
• Chloroquine-atovaquone-proguanil (chloroquine: 10 mg/kg on day 0 and 1, 5 mg/kg/day on day 2 +
atovaquone 15–25 mg/kg/day + proguanil 5–10 mg/kg/day proguanil for 3 days)
• Chloroquine-azithromycin (chloroquine: 10 mg/kg on day 0 and 1, 5 mg/kg/day on day 2 +
azithromycin 30 mg/kg once a day for 3 days)
Outcomes • Adequate clinical and parasitological response rate
• Early treatment failures; late clinical failures; PCR classification
• Adverse events (with a focus on anaemia)
• Subsequent episodes of malaria per yeara
• Incidence of chloroquine resistance marker pfcrt T76b
aAdequate clinical and parasitological response rate.
bNot assessed in quantitative synthesis in this review.
Notes Follow-up: 28 days active; 1 year passive
Countries (codes): Malawi (MWI)
Setting: health centre, peri-urban hillside township
Malaria endemicity: high transmission (> 1 case per 1000 population)
Source of funding: National Institute of Allergy and Infectious Diseases; Doris Duke Charitable Founda-
tion; Howard Hughes Medical Institute; Azithromycin donated by Pfizer, Inc; first author received inves-
tigator-initiate grant from Pfizer Global Pharmaceuticals.
Additional correspondence: we received email correspondence from M Laufer on 12 August 2018.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random sequence.
Allocation concealment
(selection bias)





High risk Open label.
Blinding of outcome as-
sessment (detection bias)
Unclear risk Open label except for (quote) "laboratory technicians who read the malaria
smears were blinded to study drug allocation".
Laufer 2012  (Continued)
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Low risk The lowest percentage of known 28-day treatment outcomes was 86.25%
across the 4 groups.
Selective reporting (re-
porting bias)
Low risk Protocol published; no evidence of reporting bias.
Other bias Low risk Quote: "The funders had no role in study design, data collection and analysis,





Methods Randomized controlled trial
Duration: 11 months; June 1995 to May 1996
Participants Adults and adolescents with uncomplicated P falciparum malaria
Number: 43
Inclusion criteria: aged 12–65 years; lifelong residents of study area
Exclusion criteria: severe malaria; mixed infections; presence of concomitant disease; inability to take
oral treatment; pregnancy/breastfeeding
Diagnosis: parasitaemia 1000–200,000 parasites/μL
Interventions • Atovaquone-proguanil (atovaquone 1000 mg + proguanil 400 mg for 3 days)
• Chloroquine (600 mg followed by 300 mg at 6, 24, and 48 hours)
• Sulfadoxine-pyrimethamine (sulfadoxine 1500 mg and pyrimethamine 75 mg single dose)
Outcomes • 2-day cure rate
• Parasite clearance timea
• Fever clearance timea
• Adverse events
aNot assessed in quantitative synthesis in this review.
Notes Follow-up: 28 days
Countries (codes): Peru (PER)
Setting: study house, Piura. Email correspondence: participants stayed in a house in an area with no
transmission of malaria for the full study duration.
Malaria endemicity: high transmission (> 1 case per 1000 population)
Source of funding: supported by a grant from GlaxoSmithKline
Additional correspondence: we received email correspondence from A Llanos-Cuentas on 16 July 2018
Risk of bias
Llanos-Cuentas 2001 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Email correspondence: computer-generated random number table, assigned
in blocks of 10.
Allocation concealment
(selection bias)





High risk Open label.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Quote: "39 analysed/43 randomised" (91%).
Selective reporting (re-
porting bias)
Low risk No evidence of reporting bias detected.
Other bias Low risk Email communication from Prof Alejandro Llanos-Cuentas 16 July 2018;





Methods Randomized controlled trial
Duration: 11 months; August 1993 to July 1994
Participants Adults and adolescents with uncomplicated P falciparum malaria
Number: 182
Inclusion criteria: aged 16–65 years; weight ≥ 40 kg
Exclusion criteria: mixed infections; concomitant disease (intercurrent febrile infections); persistent
vomiting; pregnancy/breastfeeding
Diagnosis: parasitaemia 1000–200,000 parasites/μL
Interventions • Atovaquone-proguanil (atovaquone 1000 mg + proguanil 400 mg daily for 3 days)
• Mefloquine (1250 mg over 6 hours)
Outcomes • 28-day cure rate (parasite clearance within 7 days without recrudescence during the 28-day follow-up
period)
• Parasite clearance time (from initiation of antimalarial treatment until the first time that peripheral
blood films were negative for asexual parasites)a
• Fever clearance time (from initiation of treatment until temperature < 37.2 °C, and remained < 37.2
°C for at least 24 hours)a
• Adverse events (including haematological/biochemical).
Looareesuwan 1999 
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aNot assessed in quantitative synthesis in this review.
Notes Follow-up: 28 days
Countries (codes): Thailand (THA)
Setting: Hospital for Tropical Diseases in Bangkok
Malaria endemicity: low and unstable transmission
Source of funding: supported by a grant from Glaxo Wellcome, Inc
Additional correspondence: we emailed the authors on 10 July 2018 but did not receive a reply.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described.
Allocation concealment
(selection bias)





High risk Open label.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Quote: "87% completed the study and were evaluable".
Selective reporting (re-
porting bias)
Low risk No evidence of reporting bias detected.
Other bias Unclear risk Quote: "no author has an undeclared conflict of interest".
Comment: no assurance given regarding the nature of the financial support re-





Methods Randomized controlled trial
Duration: 20 months; December 2001 to July 2003
Participants Pregnant women with uncomplicated P falciparum malaria
Number: 81
McGready 2005 
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Inclusion criteria: first episode of uncomplicated P falciparum or mixed infection; second (> 13 weeks)
or early third (< 32 weeks) trimester of pregnancy, haematocrit ≥ 20%
Exclusion criteria: known chronic disease; alcohol abuse; imminent delivery of baby; inability to toler-
ate oral treatment, inability to follow the consultation
Diagnosis: thick and thin blood films (no parasite density limit)
Interventions • Quinine (quinine sulphate 3 times daily (10 mg salt/kg every 8 hours) for 7 days)
• Artesunate-atovaquone-proguanil (artesunate 4 mg/kg/day + atovaquone 20 mg/kg/day + proguanil
8 mg/kg/day, for 3 days)
Outcomes • Fever clearance time (first time fever dropped < 37.5 °C and stayed < 37.5 °C for 48 hours). Email cor-
respondence: measured daily or before if participant complained of feeling febrile.a
• Parasite clearance time (first negative smear (if this was supported by a second consecutive negative
smear) for blood stage (trophozoites or schizonts, or both) parasites (but not including gametocytes)).
Email correspondence: blood smear performed every 24 hours.a
• PCR-adjusted cumulative cure rate over follow-up
• Anaemia




aNot assessed in quantitative synthesis in this review.
Notes Follow-up: 9 weeks in total or until delivery of baby, depending on which occurred later
Countries (codes): Thailand (THA)
Setting: antenatal clinics, Shoklo Malaria Research Unit
Malaria endemicity: low and unstable transmission
Source of funding: Wellcome Trust–Mahidol University–Oxford Tropical Medicine Research Program
Additional correspondence: we received email correspondence from R McGready on 12 July 2018. Data
on early treatment failure, day 28 and day 42 treatment failure (adjusted and unadjusted) supplied by
authors.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Computer generated in blocks of 10".
Allocation concealment
(selection bias)





High risk Open label.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Laboratory technicians blinded; therefore, low risk for laboratory outcomes;
clinicians not blinded; therefore, higher risk for clinical outcomes.
McGready 2005  (Continued)
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Low risk From email correspondence: (quote) "zero loss to follow-up at day 28".
Selective reporting (re-
porting bias)
Low risk No evidence of reporting bias detected.
Other bias Unclear risk Restricted sequential trial design to detect a reduction in treatment failure






Methods Randomized controlled trial
Duration: 5 months; December 1993 to May 1994
Participants Adults and adolescents with uncomplicated P falciparum malaria
Number: 163
Inclusion criteria: aged 12–65 years; weight ≥ 40 kg
Exclusion criteria: mixed infection; underlying disease; pregnancy/breastfeeding; persistent vomiting;
intercurrent febrile illness
Diagnosis: parasitaemia 1000–200,000 parasites/μL
Interventions • Atovaquone-proguanil (atovaquone 1000 mg + proguanil 400 mg once daily for 3 days)
• Sulfadoxine-pyrimethamine (sulfadoxine 1500 mg + pyrimethamine 75 mg single dose)
Outcomes • Cure rate day 28 (no PCR adjustment)
• Parasite clearance time (from initiation of treatment until first negative blood film)a
• Fever clearance time (from initiation of treatment until temperature < 37.5 °C and thereafter < 37.5
°C for 24 hours)a
• Adverse events
aNot assessed in quantitative synthesis in this review.
Notes Follow-up: 28 days
Countries (codes): Zambia (ZMB)
Setting: hospital
Malaria endemicity: high transmission (> 1 case per 1000 population)
Source of funding: grant from Glaxo Wellcome Research and Development
Additional correspondence: we emailed the authors on 16 July 2018 but did not receive a reply.
Risk of bias
Bias Authors' judgement Support for judgement
Mulenga 1999 
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Random sequence genera-
tion (selection bias)
Unclear risk No details given.
Allocation concealment
(selection bias)





High risk Open label.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk 98% of participants randomized had 28-day follow-up.
Selective reporting (re-
porting bias)
Low risk No evidence of selective reporting.
Other bias Unclear risk No assurance given regarding the nature of the financial support received





Methods Randomized controlled trial
Duration: 8 months, November 2000 to June 2001 (phase 1); 5 months, February 2002 to June 2002
(phase 2)
Participants Children with uncomplicated P falciparum malaria
Number: 255
Inclusion criteria: aged 6–119 months; packed cell volume < 21%; fever; weight ≥ 5 kg
Exclusion criteria: severe malaria; respiratory distress; serious concurrent illness; antimalarial drugs
within 2 weeks prior, packed cell volume > 9% (for first phase of trial, increased to > 12% for second
phase on ethics advice); unable to take oral medications; could not sit or stand supported
Diagnosis: asexual forms of P falciparum at a density of 50–500,000 parasites/µL
Interventions • Atovaquone-proguanil (atovaquone 17 mg + proguanil 7 mg/kg once daily for 3 days
• Sulfadoxine-pyrimethamine (single dose, of approximately sulfadoxine 25 mg/kg)
Outcomes • Treatment failure day 14 (need for escape medication, blood transfusion, failure to increase packed
cell volume to > 21%, death)
• Fever clearance time (first dose of the study medication until the axillary temperature decreased to
< 37.5 °C)
• Adverse events
aNot assessed in quantitative synthesis in this review.
Mulenga 2006 
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Notes Follow-up: 28 days
Countries (codes): Zambia (ZMB)
Setting: 500-bed hospital
Malaria endemicity: high transmission (> 1 case per 1000 population)
Source of funding: received financial support, atovaquone-proguanil, and matching placebo from Glax-
oSmithKline.
Additional correspondence: we emailed the authors on 16 July 2018 but did not receive a reply.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomization.
Allocation concealment
(selection bias)





Low risk Blind. Matching placebos.
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk 76% had 28-day follow-up in atovaquone-proguanil group; 75% had 28-day
follow-up in sulfadoxine-pyrimethamine group.
Selective reporting (re-
porting bias)
Low risk No evidence of reporting bias detected.
Other bias Unclear risk No assurance given regarding the nature of the financial support received





Methods Randomized controlled trial
Duration: 8 months; July 1994 to February 1995
Participants Adults with P falciparum malaria
Number: 142
Inclusion criteria: acute manifestation of malaria; aged 15–65 years; weight > 40 kg; urine test negative
for chloroquine or sulphonamides
Radlo= 1996 
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Exclusion criteria: severe malaria; mixed infection; significant concomitant disease; previous antimalar-
ials in last 2 weeks; pregnancy/breastfeeding
Diagnosis: initial parasitaemia 200–100,000 parasites/µL blood
Interventions • Atovaquone-proguanil (atovaquone 1000 mg + proguanil 400 mg once daily for 3 days)
• Amodiaquine (600 mg on admission; 600 mg at 24 hours; 300 mg at 48 hours)
Outcomes • "Cure rate" at days 14, 21, and 28
• Parasite clearance time (undefined)a
• Fever clearance time (undefined)a
• Adverse events
aNot assessed in quantitative synthesis in this review.
Notes Follow-up: 28 days
Countries (codes): Gabon (GAB)
Setting: hospital
Malaria endemicity: high transmission (> 1 case per 1000 population)
Source of funding: supported by Wellcome Research Laboratories
Additional correspondence: we emailed the authors on 12 August 2018 but did not receive a reply.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomization.
Allocation concealment
(selection bias)





High risk Open label.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk 11% of participants lost to follow-up.
Selective reporting (re-
porting bias)
Low risk No evidence of reporting bias.
Other bias Unclear risk No assurance given regarding the nature of the financial support received




Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria (Review)










Cochrane Database of Systematic Reviews
Study characteristics
Methods Randomized controlled trial
Duration: 2008–2009
Participants Children with P falciparum malaria
Number: 338
Inclusion criteria: aged 6 months to 5 years, temperature ≥ 38.0 °C
Exclusion criteria: weight < 5 kg; concomitant infectious diseases; severe malnutrition; signs of severe
and complicated malaria
Diagnosis: parasite density ≥ 2000 asexual P falciparum parasites/µL of blood, without other Plasmodi-
um species
Interventions • Artesunate-amodiaquine (artesunate 4 mg/kg bodyweight for 3 days; amodiaquine 10 mg base/kg
bodyweight for 3 days)
• Atovaquone-proguanil (atovaquone 20 mg/kg bodyweight/day for 3 days; proguanil 8 mg/kg body-
weight/day for 3 days)
• Artesunate-atovaquone-proguanil (artesunate 4 mg/kg bodyweight for 3 days; atovaquone 20 mg/kg
bodyweight/day for 3 days; proguanil 8 mg/kg bodyweight/day for 3 days)
Outcomes • Total treatment failure at day 28 (PCR adjusted and unadjusted)
• Early treatment failure
• Parasite clearance (proportion of participants with a positive blood film at day 3)a
• Fever clearance (proportion of participants with fever at day 3)a
• Adverse events
• Haematocrit improvement on day 14a
aNot assessed in quantitative synthesis in this review.
Notes Follow-up: 28 days
Countries (codes): Cameroon (CMR)
Setting: missionary dispensary, Yaoundé
Malaria endemicity: high transmission (> 1 case per 1000 population)
Source of funding: French Agence Nationale de la Recherche (grant ANR-08-MIE-024)
Additional correspondence: we emailed the authors on 9 July 2018 but did not receive a reply.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described.
Allocation concealment
(selection bias)




Unclear risk Trial registration document reported that participants were blinded but this
was not discussed in the main report.
Tahar 2014 
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All outcomes
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk 94% of participants seen at day 28.
Selective reporting (re-
porting bias)
Unclear risk Trial was retrospectively registered on 23 June 2010.





Methods Randomized controlled trial
Duration: 2 years; June 1998 to July 2000
Participants Adults and children with uncomplicated multiple-drug-resistant P falciparum malaria
Number: 1596
Inclusion criteria: weight > 10 kg
Exclusion criteria: pregnancy, use of mefloquine in previous 63 days, obtunded, vomiting, other clinical
or laboratory signs of illness
Diagnosis: slide-confirmed acute P falciparum malaria
Interventions • Artesunate-mefloquine (artesunate 4 mg/kg once daily for 3 days + mefloquine 15 mg/kg on day 1 and
10 mg/kg on day 2)
• Artesunate-atovaquone-proguanil (artesunate 4 mg/kg + atovaquone 15 mg/kg/day + proguanil 8
mg/kg/day, once daily for 3 days)
• Atovaquone-proguanil (atovaquone 15 mg/kg/day + proguanil 8 mg/kg/day once daily for 3 days)
Outcomes • Treatment failure day 42 unadjusted
• Treatment failure day 42 PCR adjusted
• Parasite clearance (proportion of participants with a positive blood film at day 3)a
• Fever clearance (proportion of participants with fever at day 2)a
• Gametocyte carriage (person gametocyte weeks)a
• Degree of anaemia (mean values)a
• Adverse events
aNot assessed in quantitative synthesis in this review.
Notes Follow-up: 42 days
Countries (codes): Thailand (THA)
Setting: Maela and Mawker Tai malaria clinics; Shoklo Malaria Research Unit
Malaria endemicity: low and unstable transmission
Van Vugt 2002 
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Source of funding: Wellcome-Trust Mahidol University Oxford Tropical Medicine Research Programme
(funded by the Wellcome Trust of Great Britain). GlaxoSmithKline donated atovaquone-proguanil
Additional correspondence: we emailed the authors on 6 October 2018 but did not receive a reply.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Randomisation was in blocks of 12".
Comment: no further details given.
Allocation concealment
(selection bias)





High risk Open label.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Quote: "88.7% (1352 of 1524) were seen at day 42".
Selective reporting (re-
porting bias)
Unclear risk Authors reported gametocyte carriage yet this outcome was not listed in the
methods. Adverse events: data together for both atovaquone-proguanil and
artesunate-atovaquone-proguanil.





Methods Randomized controlled trial
Duration: 11 months, December 2014 to December 2015
Participants Adults with P falciparum malaria or mixed P falciparum and P vivax infections
Number: 205
Inclusion criteria: aged 18–65 years
Exclusion criteria: allergic reaction/medical contraindication to study drugs; creatinine clearance < 30
mL/minute; significant acute comorbidity requiring urgent medical intervention; severe malaria; use of
antimalarial in prior 7 days, or atovaquone-proguanil in prior 30 days; use of drugs with possible inter-
actions (tetracycline, metoclopramide, rifampicin, rifabutin, zidovudine, or etoposide); pregnancy, lac-
tation, not agreeing to contraception.
Diagnosis: microscopy (asexual parasite density 100–200,000 parasites/μL)
Wojnarski 2019 
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Interventions • Atovaquone-proguanil (daily fixed dose combination of 4 tablets containing atovaquone 250 mg +
proguanil hydrochloride 100 mg (total 1000 mg/400 mg) for 3 days)
• Artesunate-atovaquone-proguanil (daily fixed dose combination of 4 tablets containing atovaquone
250 mg + proguanil hydrochloride 100 mg (total 1000 mg/400 mg daily) + 4 tablets containing arte-
sunate 50 mg (200 mg daily) for 3 days)
Both arms received a single dose of primaquine 15 mg.
Outcomes • ACPRa day 42 PCR adjusted
• ACPRa day 42 unadjusted
• ACPRa day 28 PCR adjusted
• ACPRa day 28 unadjusted
• Rates of gametocyte carriage at days 1, 4, 7, and 14 (based on combined light microscopy and PCR)b
• Parasite clearance timeb
• Adverse events
• Atovaquone levels
aAdequate clinical and parasitological response rate.
bNot assessed in quantitative synthesis in this review.
Notes Follow-up: 42 days
Countries (codes): Cambodia (KHM)
Setting: 2 hospitals
Malaria endemicity: high transmission (> 1 case per 1000 population)
Source of funding: Naval Advanced Medical Development Program, Washington DC
Additional correspondence: we emailed the authors on 4 June 2018 to determine whether trial findings
had been published in full, though this was subsequently published in 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Volunteers were randomly assigned to…with 1:1 allocation using
time-blocked randomization with a block size of 4".
Allocation concealment
(selection bias)





High risk Open label.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk 95% of participants seen at day 42.
Wojnarski 2019  (Continued)
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Selective reporting (re-
porting bias)
Low risk No evidence of reporting bias.
Other bias Low risk The funding source had no role in the analysis or interpretation of the data,
preparation of the manuscript or the decision to publish.
Wojnarski 2019  (Continued)
ALT: alanine aminotransferase; P falciparum: Plasmodium falciparum; PCR: polymerase chain reaction; ULN: upper limits of normal.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Bustos 1999 Participants were initially randomized to receive either atovaquone-proguanil or chloroquine.
However, because of a low cure rates in the chloroquine group, future participants were addition-
ally given sulfadoxine-pyrimethamine. The data were presented as though this was a 3-arm trial,
but we considered that data for 2 atovaquone-proguanil groups (those recruited before and after
the addition of sulfadoxine-pyrimethamine) would be needed to compare these separately with
chloroquine and chloroquine-sulfadoxine-pyrimethamine.
Gupta 2005 This report was part of an already included trial (Van Vugt 2002).
Hitani 2006 Retrospective data; intervention arms were not randomized.
Krudsood 2007 Single arm trial.
Looareesuwan 1996 Unclear study design with non-randomized methodology.
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Atovaquone-proguanil (AV+PG) versus artemether-lumefantrine (AL)





Statistical method Effect size
1.1 Total failure day 28 PCR-adjusted 1 60 Risk Ratio (M-H, Fixed, 95% CI) 5.00 [0.25, 99.95]
1.2 Total failure day 42 PCR-adjusted 1 208 Risk Ratio (M-H, Fixed, 95% CI) 3.00 [0.19, 47.12]
1.3 Total failure day 42 PCR-unadjusted 1 60 Risk Ratio (M-H, Fixed, 95% CI) 5.00 [0.25, 99.95]
1.4 Adverse events 2 2236 Risk Ratio (M-H, Fixed, 95% CI) 2.35 [1.57, 3.53]
1.4.1 Serious adverse events 2 272 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.4.2 Adverse events leading to withdraw-
al
2 272 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.4.3 Headaches 2 272 Risk Ratio (M-H, Fixed, 95% CI) 2.54 [1.17, 5.51]
1.4.4 Diarrhoea 2 272 Risk Ratio (M-H, Fixed, 95% CI) 2.25 [0.48, 10.54]
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Statistical method Effect size
1.4.5 Gastrointestinal and abdominal
pains
1 212 Risk Ratio (M-H, Fixed, 95% CI) 2.00 [0.34, 11.65]
1.4.6 Nausea and vomiting 2 272 Risk Ratio (M-H, Fixed, 95% CI) 10.00 [2.73, 36.60]
1.4.7 Dizziness 1 212 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.58, 4.75]
1.4.8 Hearing problem 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.87]
1.4.9 Inner ear signs and symptoms 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 3.03]
1.4.10 Feelings and sensations 1 60 Risk Ratio (M-H, Fixed, 95% CI) 3.00 [0.33, 27.23]
1.4.11 Febrile disorders 2 272 Risk Ratio (M-H, Fixed, 95% CI) 2.25 [0.77, 6.60]
 
 
Analysis 1.1.   Comparison 1: Atovaquone-proguanil (AV+PG) versus






Test for overall effect: Z = 1.05 (P = 0.29)
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Analysis 1.2.   Comparison 1: Atovaquone-proguanil (AV+PG) versus






Test for overall effect: Z = 0.78 (P = 0.43)
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Analysis 1.3.   Comparison 1: Atovaquone-proguanil (AV+PG) versus






Test for overall effect: Z = 1.05 (P = 0.29)
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Analysis 1.4.   Comparison 1: Atovaquone-proguanil (AV+PG) versus artemether-lumefantrine (AL), Outcome 4:
Adverse events
Study or Subgroup






Test for overall effect: Not applicable












Heterogeneity: Chi² = 1.59, df = 1 (P = 0.21); I² = 37%






Heterogeneity: Chi² = 0.05, df = 1 (P = 0.82); I² = 0%
Test for overall effect: Z = 1.03 (P = 0.30)





Test for overall effect: Z = 0.77 (P = 0.44)





Heterogeneity: Chi² = 0.71, df = 1 (P = 0.40); I² = 0%
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Test for overall effect: Z = 0.68 (P = 0.50)





Test for overall effect: Z = 0.98 (P = 0.33)











Heterogeneity: Chi² = 0.10, df = 1 (P = 0.75); I² = 0%
Test for overall effect: Z = 1.48 (P = 0.14)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 12.01, df = 12 (P = 0.44); I² = 0%
Test for overall effect: Z = 4.12 (P < 0.0001)
























































1.67 [0.58 , 4.75]
0.33 [0.01 , 7.87]
0.33 [0.01 , 7.87]
0.33 [0.04 , 3.03]
0.33 [0.04 , 3.03]
3.00 [0.33 , 27.23]
3.00 [0.33 , 27.23]
2.00 [0.59 , 6.82]
3.00 [0.33 , 27.23]
2.25 [0.77 , 6.60]
2.35 [1.57 , 3.53]
0.001 0.1 1 10 1000
Favours AV+PG Favours AL
Footnotes
(1) No medDRA term.
(2) Original term was 'shivering'.
 
 
Comparison 2.   Atovaquone-proguanil (AV+PG) versus artesunate-amodiaquine (AS+AQ)





Statistical method Effect size
2.1 Total failure day 28 PCR-adjust-
ed
1 132 Risk Ratio (M-H, Fixed, 95% CI) 3.19 [0.67, 15.22]
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Statistical method Effect size
2.2 Total failure day 28 PCR-unad-
justed
1 132 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.49, 2.91]
2.3 Early treatment failure 1 132 Risk Ratio (M-H, Fixed, 95% CI) 13.80 [0.79, 240.11]
2.4 Adverse events 1 278 Risk Ratio (M-H, Fixed, 95% CI) 3.04 [0.13, 73.43]
2.4.1 Serious adverse events 1 139 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2.4.2 Adverse events leading to
withdrawal
1 139 Risk Ratio (M-H, Fixed, 95% CI) 3.04 [0.13, 73.43]
 
 
Analysis 2.1.   Comparison 2: Atovaquone-proguanil (AV+PG) versus artesunate-






Test for overall effect: Z = 1.45 (P = 0.15)
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Footnotes
(1) Study described 'early treatment failures' included in total treatment failures as PCR was performed at day 7 and day 28.
 
 
Analysis 2.2.   Comparison 2: Atovaquone-proguanil (AV+PG) versus artesunate-






Test for overall effect: Z = 0.39 (P = 0.69)



















M-H, Fixed, 95% CI
1.20 [0.49 , 2.91]
1.20 [0.49 , 2.91]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+PG Favours AS+AQ
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Analysis 2.3.   Comparison 2: Atovaquone-proguanil (AV+PG) versus






Test for overall effect: Z = 1.80 (P = 0.07)



















M-H, Fixed, 95% CI
13.80 [0.79 , 240.11]
13.80 [0.79 , 240.11]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+PG Favours AS+AQ
 
 
Analysis 2.4.   Comparison 2: Atovaquone-proguanil (AV+PG) versus
artesunate-amodiaquine (AS+AQ), Outcome 4: Adverse events
Study or Subgroup





Test for overall effect: Not applicable









Test for overall effect: Z = 0.69 (P = 0.49)
































M-H, Fixed, 95% CI
Not estimable
Not estimable
3.04 [0.13 , 73.43]
3.04 [0.13 , 73.43]
3.04 [0.13 , 73.43]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+PG Favours AS+AQ
 
 
Comparison 3.   Atovaquone-proguanil (AV+PG) versus artesunate-mefloquine (AS+MQ)





Statistical method Effect size
3.1 Total failure day 42 PCR-adjusted 2 1168 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.57, 2.34]
3.2 Total failure day 42 PCR-unadjusted 1 1063 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.50, 1.30]
3.3 Adverse events 2 5312 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.60, 0.99]
3.3.1 Serious adverse events 2 1275 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.10, 4.22]
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Statistical method Effect size
3.3.2 Adverse events leading to withdraw-
al
2 1275 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.04, 23.89]
3.3.3 Headaches 1 212 Risk Ratio (M-H, Fixed, 95% CI) 3.00 [1.10, 8.16]
3.3.4 Diarrhoea 1 212 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.18, 4.00]
3.3.5 Gastrointestinal and abdominal
pains
1 212 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.28, 7.96]
3.3.6 Nausea and vomiting 2 896 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.44, 0.89]
3.3.7 Disturbances in initiating and main-
taining sleep
1 212 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.02, 6.02]
3.3.8 Feelings and sensations 1 594 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.34, 1.02]
3.3.9 Dizziness 1 212 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.41, 2.83]
3.3.10 Febrile disorders 1 212 Risk Ratio (M-H, Fixed, 95% CI) 6.00 [1.13, 31.83]
 
 
Analysis 3.1.   Comparison 3: Atovaquone-proguanil (AV+PG) versus artesunate-
mefloquine (AS+MQ), Outcome 1: Total failure day 42 PCR-adjusted
Study or Subgroup
Carrasquilla 2012 (1)
Van Vugt 2002 (2)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 0.01, df = 1 (P = 0.93); I² = 0%
Test for overall effect: Z = 0.39 (P = 0.70)
























M-H, Fixed, 95% CI
1.02 [0.07 , 15.87]
1.16 [0.56 , 2.41]
1.15 [0.57 , 2.34]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+PG Favours AS+MQ
Footnotes
(1) Data unclear. 51/52 had PCR-adjusted cure.
(2) Authors reported missing data as treatment failures; denominator is number randomised, not evaluable population.
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Analysis 3.2.   Comparison 3: Atovaquone-proguanil (AV+PG) versus artesunate-
mefloquine (AS+MQ), Outcome 2: Total failure day 42 PCR-unadjusted
Study or Subgroup




Test for overall effect: Z = 0.88 (P = 0.38)



















M-H, Fixed, 95% CI
0.80 [0.50 , 1.30]
0.80 [0.50 , 1.30]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+PG Favours AS+MQ
Footnotes
(1) Authors reported missing data as treatment failures; denominator is number randomised, not evaluable population.
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Analysis 3.3.   Comparison 3: Atovaquone-proguanil (AV+PG) versus artesunate-mefloquine (AS+MQ), Outcome 3:
Adverse events
Study or Subgroup





Heterogeneity: Chi² = 0.11, df = 1 (P = 0.74); I² = 0%
Test for overall effect: Z = 0.47 (P = 0.64)


















Test for overall effect: Z = 0.20 (P = 0.84)





Test for overall effect: Z = 0.48 (P = 0.63)
3.3.6 Nausea and vomiting
Carrasquilla 2012
Van Vugt 2002 (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 8.84, df = 1 (P = 0.003); I² = 89%
Test for overall effect: Z = 2.60 (P = 0.009)


































































































M-H, Fixed, 95% CI
0.99 [0.04 , 23.89]
0.50 [0.05 , 5.53]
0.64 [0.10 , 4.22]
0.99 [0.04 , 23.89]
Not estimable
0.99 [0.04 , 23.89]
3.00 [1.10 , 8.16]
3.00 [1.10 , 8.16]
0.86 [0.18 , 4.00]
0.86 [0.18 , 4.00]
1.50 [0.28 , 7.96]
1.50 [0.28 , 7.96]
1.80 [0.84 , 3.87]
0.48 [0.32 , 0.73]
0.63 [0.44 , 0.89]
0.33 [0.02 , 6.02]
0.33 [0.02 , 6.02]
Risk Ratio
M-H, Fixed, 95% CI
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Analysis 3.3.   (Continued)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
3.3.8 Feelings and sensations
















Test for overall effect: Z = 2.10 (P = 0.04)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 25.04, df = 11 (P = 0.009); I² = 56%
Test for overall effect: Z = 2.04 (P = 0.04)




































0.59 [0.34 , 1.02]
0.59 [0.34 , 1.02]
1.07 [0.41 , 2.83]
1.07 [0.41 , 2.83]
6.00 [1.13 , 31.83]
6.00 [1.13 , 31.83]
0.77 [0.60 , 0.99]
0.01 0.1 1 10 100
Favours AV+PG Favours AS+MQ
Footnotes
(1) This only included reported adverse event 'nausea' and not 'early vomiting' or 'late vomiting'.
(2) Original term was 'chills/rigours'.
 
 
Comparison 4.   Atovaquone-proguanil (AV+PG) versus artesunate-atovaquone-proguanil (AS+AV+PG)





Statistical method Effect size
4.1 Total failure day 28 PCR-adjust-
ed
2 375 Risk Ratio (M-H, Fixed, 95% CI) 5.14 [0.61, 43.52]
4.2 Total failure day 28 PCR-unad-
justed
1 187 Risk Ratio (M-H, Fixed, 95% CI) 15.48 [0.90, 267.27]
4.3 Total failure day 42 PCR-adjust-
ed
2 1258 Risk Ratio (M-H, Fixed, 95% CI) 1.84 [0.95, 3.56]
4.4 Total failure day 42 PCR-unad-
justed
1 1063 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [0.88, 2.79]
4.5 Early treatment failure 2 395 Risk Ratio (M-H, Fixed, 95% CI) 5.11 [0.25, 104.94]
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Statistical method Effect size
4.6 Adverse events 3 4732 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.43, 0.76]
4.6.1 Serious adverse events 3 1455 Risk Ratio (M-H, Fixed, 95% CI) 1.66 [0.22, 12.49]
4.6.2 Adverse events leading to
withdrawal
2 1250 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4.6.3 Nausea and vomiting 1 664 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.34, 0.80]
4.6.4 Gastrointestinal and abdomi-
nal pains
1 752 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.33, 1.04]
4.6.5 Feelings and sensations 1 611 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.35, 1.04]
 
 
Analysis 4.1.   Comparison 4: Atovaquone-proguanil (AV+PG) versus artesunate-






Heterogeneity: Chi² = 0.15, df = 1 (P = 0.70); I² = 0%
Test for overall effect: Z = 1.50 (P = 0.13)
























M-H, Fixed, 95% CI
7.23 [0.38 , 137.98]
3.06 [0.13 , 74.26]
5.14 [0.61 , 43.52]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+PG Favours AS+AV+PG
 
 
Analysis 4.2.   Comparison 4: Atovaquone-proguanil (AV+PG) versus artesunate-






Test for overall effect: Z = 1.89 (P = 0.06)



















M-H, Fixed, 95% CI
15.48 [0.90 , 267.27]
15.48 [0.90 , 267.27]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+PG Favours AS+AV+PG
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Analysis 4.3.   Comparison 4: Atovaquone-proguanil (AV+PG) versus artesunate-
atovaquone-proguanil (AS+AV+PG), Outcome 3: Total failure day 42 PCR-adjusted
Study or Subgroup




Heterogeneity: Chi² = 2.10, df = 1 (P = 0.15); I² = 52%
Test for overall effect: Z = 1.82 (P = 0.07)
























M-H, Fixed, 95% CI
3.02 [1.10 , 8.24]
1.11 [0.45 , 2.77]
1.84 [0.95 , 3.56]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+PG Favours AS+AV+PG
Footnotes
(1) Authors reported missing data as treatment failures; denominator is number randomised, not evaluable population.
 
 
Analysis 4.4.   Comparison 4: Atovaquone-proguanil (AV+PG) versus artesunate-
atovaquone-proguanil (AS+AV+PG), Outcome 4: Total failure day 42 PCR-unadjusted
Study or Subgroup




Test for overall effect: Z = 1.51 (P = 0.13)



















M-H, Fixed, 95% CI
1.56 [0.88 , 2.79]
1.56 [0.88 , 2.79]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+PG Favours AS+AV+PG
Footnotes
(1) Authors reported missing data as treatment failures; denominator is number randomised, not evaluable population.
 
 
Analysis 4.5.   Comparison 4: Atovaquone-proguanil (AV+PG) versus artesunate-







Test for overall effect: Z = 1.06 (P = 0.29)























M-H, Fixed, 95% CI
5.11 [0.25 , 104.94]
Not estimable
5.11 [0.25 , 104.94]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+PG Favours AS+AV+PG
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Analysis 4.6.   Comparison 4: Atovaquone-proguanil (AV+PG) versus
artesunate-atovaquone-proguanil (AS+AV+PG), Outcome 6: Adverse events
Study or Subgroup






Heterogeneity: Chi² = 0.27, df = 1 (P = 0.60); I² = 0%
Test for overall effect: Z = 0.49 (P = 0.62)






Test for overall effect: Not applicable
4.6.3 Nausea and vomiting




Test for overall effect: Z = 3.02 (P = 0.003)





Test for overall effect: Z = 1.84 (P = 0.07)





Test for overall effect: Z = 1.81 (P = 0.07)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 1.42, df = 4 (P = 0.84); I² = 0%
Test for overall effect: Z = 3.82 (P = 0.0001)











































































M-H, Fixed, 95% CI
Not estimable
3.02 [0.12 , 73.89]
0.99 [0.06 , 15.62]




0.52 [0.34 , 0.80]
0.52 [0.34 , 0.80]
0.59 [0.33 , 1.04]
0.59 [0.33 , 1.04]
0.60 [0.35 , 1.04]
0.60 [0.35 , 1.04]
0.57 [0.43 , 0.76]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+PG Favours AS+AV+PG
Footnotes
(1) Included adverse event 'nausea' only (not 'early/late vomiting').
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Comparison 5.   Atovaquone-proguanil (AV+PG) versus dihydroartemisinin-piperaquine-trimethoprim-primaquine
(CV8)





Statistical method Effect size
5.1 Total failure day 28 PCR-unadjust-
ed
1 161 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.36, 4.66]
5.2 Early treatment failure 1 161 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5.3 Adverse events 1 1155 Risk Ratio (M-H, Fixed, 95% CI) 1.90 [0.71, 5.11]
5.3.1 Serious adverse events 1 165 Risk Ratio (M-H, Fixed, 95% CI) 5.18 [0.25, 106.33]
5.3.2 Adverse events leading to with-
drawal
1 165 Risk Ratio (M-H, Fixed, 95% CI) 5.18 [0.25, 106.33]
5.3.3 Nausea and vomiting 1 165 Risk Ratio (M-H, Fixed, 95% CI) 5.18 [0.25, 106.33]
5.3.4 Diarrhoea 1 165 Risk Ratio (M-H, Fixed, 95% CI) 3.11 [0.13, 75.24]
5.3.5 Headaches 1 165 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.01, 8.36]
5.3.6 Oral dryness and saliva altered 1 165 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.01, 8.36]
5.3.7 Pruritis 1 165 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.07, 16.30]
 
 
Analysis 5.1.   Comparison 5: Atovaquone-proguanil (AV+PG) versus dihydroartemisinin-






Test for overall effect: Z = 0.40 (P = 0.69)



















M-H, Fixed, 95% CI
1.30 [0.36 , 4.66]
1.30 [0.36 , 4.66]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+PG Favours CV8
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Analysis 5.2.   Comparison 5: Atovaquone-proguanil (AV+PG) versus dihydroartemisinin-






Test for overall effect: Not applicable





















M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+PG Favours CV8
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Analysis 5.3.   Comparison 5: Atovaquone-proguanil (AV+PG) versus dihydroartemisinin-piperaquine-trimethoprim-
primaquine (CV8), Outcome 3: Adverse events
Study or Subgroup





Test for overall effect: Z = 1.07 (P = 0.29)





Test for overall effect: Z = 1.07 (P = 0.29)

















Test for overall effect: Z = 0.65 (P = 0.51)











Test for overall effect: Z = 0.03 (P = 0.98)
Total (95% CI)
Total events:




















































































M-H, Fixed, 95% CI
5.18 [0.25 , 106.33]
5.18 [0.25 , 106.33]
5.18 [0.25 , 106.33]
5.18 [0.25 , 106.33]
5.18 [0.25 , 106.33]
5.18 [0.25 , 106.33]
3.11 [0.13 , 75.24]
3.11 [0.13 , 75.24]
0.35 [0.01 , 8.36]
0.35 [0.01 , 8.36]
0.35 [0.01 , 8.36]
0.35 [0.01 , 8.36]
1.04 [0.07 , 16.30]
1.04 [0.07 , 16.30]
1.90 [0.71 , 5.11]
Risk Ratio
M-H, Fixed, 95% CI
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Analysis 5.3.   (Continued)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 3.75, df = 6 (P = 0.71); I² = 0%
Test for overall effect: Z = 1.27 (P = 0.20)




588 100.0% 1.90 [0.71 , 5.11]
0.01 0.1 1 10 100
Favours AV+PG Favours CV8
 
 
Comparison 6.   Atovaquone-proguanil (AV+PG) versus quinine-tetracycline (QN+TET)





Statistical method Effect size
6.1 Total failure day 28 PCR-unadjust-
ed
1 142 Risk Ratio (M-H, Fixed, 95% CI) 2.84 [0.12, 68.51]
6.2 Early treatment failure 1 142 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6.3 Adverse events 1 1694 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.37, 0.60]
6.3.1 Serious adverse events 1 154 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6.3.2 Adverse events leading to with-
drawal
1 154 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6.3.3 Gastrointestinal and abdominal
pains
1 154 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.64, 1.93]
6.3.4 Nausea and vomiting 1 154 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.29, 1.02]
6.3.5 Asthenic conditions 1 154 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.28, 1.29]
6.3.6 Diarrhoea 1 154 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.20, 1.58]
6.3.7 Headaches 1 154 Risk Ratio (M-H, Fixed, 95% CI) 1.89 [0.90, 3.97]
6.3.8 Dizziness 1 154 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.14, 0.48]
6.3.9 Pruritis 1 154 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.44, 5.11]
6.3.10 Auditory nerve disorders 1 154 Risk Ratio (M-H, Fixed, 95% CI) 0.05 [0.02, 0.17]
6.3.11 Appetite disorders 1 154 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.14, 1.03]
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Analysis 6.1.   Comparison 6: Atovaquone-proguanil (AV+PG) versus quinine-






Test for overall effect: Z = 0.64 (P = 0.52)



















M-H, Fixed, 95% CI
2.84 [0.12 , 68.51]
2.84 [0.12 , 68.51]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+PG Favours QN+TET
 
 
Analysis 6.2.   Comparison 6: Atovaquone-proguanil (AV+PG) versus






Test for overall effect: Not applicable





















M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+PG Favours QN+TET
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Analysis 6.3.   Comparison 6: Atovaquone-proguanil (AV+PG) versus quinine-tetracycline (QN+TET), Outcome 3:
Adverse events
Study or Subgroup
6.3.1 Serious adverse events




Test for overall effect: Not applicable
6.3.2 Adverse events leading to withdrawal




Test for overall effect: Not applicable
6.3.3 Gastrointestinal and abdominal pains




Test for overall effect: Z = 0.37 (P = 0.71)
6.3.4 Nausea and vomiting




Test for overall effect: Z = 1.89 (P = 0.06)
6.3.5 Asthenic conditions




Test for overall effect: Z = 1.31 (P = 0.19)
6.3.6 Diarrhoea




Test for overall effect: Z = 1.10 (P = 0.27)
6.3.7 Headaches




Test for overall effect: Z = 1.68 (P = 0.09)
6.3.8 Dizziness

























































































1.11 [0.64 , 1.93]
1.11 [0.64 , 1.93]
0.55 [0.29 , 1.02]
0.55 [0.29 , 1.02]
0.60 [0.28 , 1.29]
0.60 [0.28 , 1.29]
0.56 [0.20 , 1.58]
0.56 [0.20 , 1.58]
1.89 [0.90 , 3.97]
1.89 [0.90 , 3.97]
0.26 [0.14 , 0.48]
0.26 [0.14 , 0.48]
Risk Ratio
M-H, Fixed, 95% CI
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Analysis 6.3.   (Continued)
6.3.8 Dizziness




Test for overall effect: Z = 4.31 (P < 0.0001)
6.3.9 Pruritis




Test for overall effect: Z = 0.65 (P = 0.52)
6.3.10 Auditory nerve disorders




Test for overall effect: Z = 5.10 (P < 0.00001)
6.3.11 Appetite disorders




Test for overall effect: Z = 1.91 (P = 0.06)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 44.83, df = 8 (P < 0.00001); I² = 82%
Test for overall effect: Z = 6.26 (P < 0.00001)














































0.26 [0.14 , 0.48]
0.26 [0.14 , 0.48]
1.50 [0.44 , 5.11]
1.50 [0.44 , 5.11]
0.05 [0.02 , 0.17]
0.05 [0.02 , 0.17]
0.38 [0.14 , 1.03]
0.38 [0.14 , 1.03]
0.47 [0.37 , 0.60]
0.01 0.1 1 10 100
Favours AV+PG Favours QN+TET
Footnotes
(1) Denominator formed from participants completing treatment.
(2) Denominator formed from participants completing treatment. Included adverse event 'nausea' only (not 'vomiting').
 
 
Comparison 7.   Atovaquone-proguanil (AV+PG) versus sulfadoxine-pyrimethamine (SP)





Statistical method Effect size
7.1 Total failure day 28 PCR-adjusted 1 192 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.92]
7.2 Total failure day 28 PCR-unadjusted 3 364 Risk Ratio (M-H, Fixed, 95% CI) 0.24 [0.10, 0.59]
7.3 Early treatment failure 2 172 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.06]
7.4 Adverse events 3 5569 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.84, 1.23]
7.4.1 Serious adverse events 3 447 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.35, 1.41]
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Statistical method Effect size
7.4.2 Adverse events leading to withdrawal 3 447 Risk Ratio (M-H, Fixed, 95% CI) 5.95 [0.73, 48.75]
7.4.3 Gastrointestinal and abdominal pains 2 192 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.78, 2.18]
7.4.4 Diarrhoea 2 418 Risk Ratio (M-H, Fixed, 95% CI) 1.38 [0.65, 2.96]
7.4.5 Nausea and vomiting 2 192 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.47, 1.74]
7.4.6 Headaches 2 192 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.56, 1.42]
7.4.7 Hypotensive disorders 1 163 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.17, 1.05]
7.4.8 Seizure and seizure disorders 2 284 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.08, 5.43]
7.4.9 Appetite disorders 2 192 Risk Ratio (M-H, Fixed, 95% CI) 1.61 [0.52, 5.00]
7.4.10 Hepatobiliary signs and symptoms 1 163 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.30, 3.28]
7.4.11 Pruritis 2 192 Risk Ratio (M-H, Fixed, 95% CI) 1.41 [0.35, 5.67]
7.4.12 Spleen disorders 1 163 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [0.25, 8.64]
7.4.13 Cardiac signs and symptoms 1 163 Risk Ratio (M-H, Fixed, 95% CI) 6.92 [0.36, 131.79]
7.4.14 Disturbances in initiating and main-
taining sleep
1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.09, 1.21]
7.4.15 Feelings and sensations 1 29 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [0.06, 32.05]
7.4.16 Rubeola viral infections 1 255 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.11, 3.89]
7.4.17 Hypoglycaemic conditions 1 255 Risk Ratio (M-H, Fixed, 95% CI) 4.96 [0.24, 102.33]
7.4.18 Lower respiratory tract and lung in-
fections
1 255 Risk Ratio (M-H, Fixed, 95% CI) 2.48 [0.49, 12.55]
7.4.19 Anaemias 1 255 Risk Ratio (M-H, Fixed, 95% CI) 2.98 [0.12, 72.39]
7.4.20 Sepsis, bacteraemia, viraemia, fun-
gaemia
1 255 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.03, 3.14]
7.4.21 Breathing abnormalities 1 255 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 1.61]
7.4.22 Muscle pains 1 163 Risk Ratio (M-H, Fixed, 95% CI) 1.58 [0.54, 4.63]
7.4.23 Asthenic conditions 2 418 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.68, 2.28]
7.4.24 Dizziness 2 192 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.28, 1.81]
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Analysis 7.1.   Comparison 7: Atovaquone-proguanil (AV+PG) versus






Test for overall effect: Z = 0.69 (P = 0.49)
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0.33 [0.01 , 7.92]
0.33 [0.01 , 7.92]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+AG Favours SP
 
 
Analysis 7.2.   Comparison 7: Atovaquone-proguanil (AV+PG) versus sulfadoxine-







Heterogeneity: Chi² = 0.04, df = 1 (P = 0.83); I² = 0%
Test for overall effect: Z = 3.13 (P = 0.002)




























M-H, Fixed, 95% CI
Not estimable
0.33 [0.01 , 8.06]
0.23 [0.09 , 0.59]
0.24 [0.10 , 0.59]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+AG Favours SP
 
 
Analysis 7.3.   Comparison 7: Atovaquone-proguanil (AV+PG) versus







Test for overall effect: Z = 0.68 (P = 0.50)























M-H, Fixed, 95% CI
Not estimable
0.33 [0.01 , 8.06]
0.33 [0.01 , 8.06]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+AG Favours SP
Footnotes
(1) Denominator for AV+PG formed from addition of 'phase 1' and 'phase 2' trial data.
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Analysis 7.4.   Comparison 7: Atovaquone-proguanil (AV+PG) versus sulfadoxine-pyrimethamine (SP), Outcome 4:
Adverse events
Study or Subgroup







Test for overall effect: Z = 1.00 (P = 0.32)







Test for overall effect: Z = 1.66 (P = 0.10)





Heterogeneity: Chi² = 0.05, df = 1 (P = 0.83); I² = 0%






Heterogeneity: Chi² = 0.06, df = 1 (P = 0.80); I² = 0%
Test for overall effect: Z = 0.84 (P = 0.40)





Heterogeneity: Chi² = 0.84, df = 1 (P = 0.36); I² = 0%






Heterogeneity: Chi² = 0.62, df = 1 (P = 0.43); I² = 0%
















































































































M-H, Fixed, 95% CI
Not estimable
Not estimable
0.70 [0.35 , 1.41]
0.70 [0.35 , 1.41]
Not estimable
Not estimable
5.95 [0.73 , 48.75]
5.95 [0.73 , 48.75]
1.13 [0.27 , 4.74]
1.34 [0.77 , 2.31]
1.31 [0.78 , 2.18]
1.43 [0.65 , 3.15]
0.99 [0.06 , 15.69]
1.38 [0.65 , 2.96]
1.57 [0.40 , 6.14]
0.76 [0.35 , 1.63]
0.90 [0.47 , 1.74]
0.45 [0.07 , 2.71]
0.95 [0.58 , 1.53]
0.90 [0.56 , 1.42]
0.42 [0.17 , 1.05]
Risk Ratio
M-H, Fixed, 95% CI
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Test for overall effect: Z = 1.86 (P = 0.06)





Heterogeneity: Chi² = 0.42, df = 1 (P = 0.52); I² = 0%






Heterogeneity: Chi² = 0.09, df = 1 (P = 0.77); I² = 0%
Test for overall effect: Z = 0.83 (P = 0.41)











Heterogeneity: Chi² = 2.76, df = 1 (P = 0.10); I² = 64%






Test for overall effect: Z = 0.44 (P = 0.66)





Test for overall effect: Z = 1.29 (P = 0.20)



































































































0.42 [0.17 , 1.05]
0.42 [0.17 , 1.05]
1.43 [0.06 , 32.05]
0.33 [0.01 , 8.04]
0.67 [0.08 , 5.43]
2.38 [0.13 , 45.11]
1.48 [0.43 , 5.06]
1.61 [0.52 , 5.00]
0.99 [0.30 , 3.28]
0.99 [0.30 , 3.28]
0.16 [0.01 , 3.56]
3.95 [0.45 , 34.60]
1.41 [0.35 , 5.67]
1.48 [0.25 , 8.64]
1.48 [0.25 , 8.64]
6.92 [0.36 , 131.79]
6.92 [0.36 , 131.79]
0.34 [0.09 , 1.21]
0.34 [0.09 , 1.21]
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Test for overall effect: Z = 1.67 (P = 0.09)





Test for overall effect: Z = 0.22 (P = 0.82)











Test for overall effect: Z = 1.04 (P = 0.30)











Test for overall effect: Z = 0.67 (P = 0.50)





























































































0.34 [0.09 , 1.21]
0.34 [0.09 , 1.21]
1.43 [0.06 , 32.05]
1.43 [0.06 , 32.05]
0.66 [0.11 , 3.89]
0.66 [0.11 , 3.89]
4.96 [0.24 , 102.33]
4.96 [0.24 , 102.33]
2.48 [0.49 , 12.55]
2.48 [0.49 , 12.55]
2.98 [0.12 , 72.39]
2.98 [0.12 , 72.39]
0.33 [0.03 , 3.14]
0.33 [0.03 , 3.14]
0.09 [0.01 , 1.61]
0.09 [0.01 , 1.61]
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Heterogeneity: Chi² = 1.62, df = 1 (P = 0.20); I² = 38%






Heterogeneity: Chi² = 0.22, df = 1 (P = 0.64); I² = 0%
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 30.00, df = 32 (P = 0.57); I² = 0%
Test for overall effect: Z = 0.18 (P = 0.86)














































1.58 [0.54 , 4.63]
1.58 [0.54 , 4.63]
1.44 [0.76 , 2.72]
0.20 [0.01 , 4.09]
1.24 [0.68 , 2.28]
1.43 [0.06 , 32.05]
0.66 [0.25 , 1.77]
0.71 [0.28 , 1.81]
1.02 [0.84 , 1.23]
0.01 0.1 1 10 100
Favours AV+AG Favours SP
Footnotes
(1) Denominator for AV+PG formed from addition of 'phase 1' and 'phase 2' trial data.
(2) AV+PG group: 6 deaths. SP group: 1 death.
(3) Denominator for AV+PG formed from addition of 'phase 1' and 'phase 2' trial data. Included adverse event 'vomiting' only (not 'nausea').
(4) Included adverse event 'vomiting' only (not 'nausea').
(5) Original reported symptom 'lethargy'.
 
 
Comparison 8.   Atovaquone-proguanil (AV+PG) versus quinine (QN)





Statistical method Effect size
8.1 Total failure day 28 PCR-adjusted 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.12, 3.71]
8.2 Total failure day 42 PCR-unadjusted 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.06, 1.26]
8.3 Early treatment failure 1 66 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
8.4 Adverse events 1 660 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.44, 1.49]
8.4.1 Serious adverse events 1 60 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
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Statistical method Effect size
8.4.2 Adverse events leading to withdraw-
al
1 60 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
8.4.3 Inner ear signs and symptoms 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.87]
8.4.4 Febrile disorders 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.16, 2.29]
8.4.5 Feelings and sensations 1 60 Risk Ratio (M-H, Fixed, 95% CI) 3.00 [0.33, 27.23]
8.4.6 Headaches 1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.41, 3.51]
8.4.7 Nausea and vomiting 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.05, 5.22]
8.4.8 Diarrhoea 1 60 Risk Ratio (M-H, Fixed, 95% CI) 3.00 [0.13, 70.83]
8.4.9 Appetite disorders 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.87]
8.4.10 Hearing problem 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.87]
8.4.11 Auditory nerve disorders 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 3.03]
 
 
Analysis 8.1.   Comparison 8: Atovaquone-proguanil (AV+PG)






Test for overall effect: Z = 0.46 (P = 0.64)
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Analysis 8.2.   Comparison 8: Atovaquone-proguanil (AV+PG) versus






Test for overall effect: Z = 1.65 (P = 0.10)



















M-H, Fixed, 95% CI
0.29 [0.06 , 1.26]
0.29 [0.06 , 1.26]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+PG Favours QN
Footnotes
(1) Denominator formed from number of participants at day 28 (unclear rate of drop out by day 42).
 
 






Test for overall effect: Not applicable
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Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria (Review)










Cochrane Database of Systematic Reviews
Analysis 8.4.   Comparison 8: Atovaquone-proguanil (AV+PG) versus quinine (QN), Outcome 4: Adverse events
Study or Subgroup





Test for overall effect: Not applicable





Test for overall effect: Not applicable











Test for overall effect: Z = 0.75 (P = 0.45)











Test for overall effect: Z = 0.33 (P = 0.74)




























































































0.33 [0.01 , 7.87]
0.33 [0.01 , 7.87]
0.60 [0.16 , 2.29]
0.60 [0.16 , 2.29]
3.00 [0.33 , 27.23]
3.00 [0.33 , 27.23]
1.20 [0.41 , 3.51]
1.20 [0.41 , 3.51]
0.50 [0.05 , 5.22]
0.50 [0.05 , 5.22]
3.00 [0.13 , 70.83]
Risk Ratio
M-H, Fixed, 95% CI
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Test for overall effect: Z = 0.68 (P = 0.50)





Test for overall effect: Z = 0.98 (P = 0.33)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 4.41, df = 8 (P = 0.82); I² = 0%
Test for overall effect: Z = 0.68 (P = 0.50)














































3.00 [0.13 , 70.83]
3.00 [0.13 , 70.83]
0.33 [0.01 , 7.87]
0.33 [0.01 , 7.87]
0.33 [0.01 , 7.87]
0.33 [0.01 , 7.87]
0.33 [0.04 , 3.03]
0.33 [0.04 , 3.03]
0.81 [0.44 , 1.49]
0.01 0.1 1 10 100
Favours AV+PG Favours QN
Footnotes
(1) Denominator formed from number of participants with adverse events at day 28.
(2) Denominator formed from number of participants with adverse event at day 28.
(3) Denominator formed from number of participants with adverse event at day 28. Original symptom term 'shivering'.
(4) Denominator formed from number of participants with adverse event at day 28. No medDRA term.
 
 
Comparison 9.   Atovaquone-proguanil (AV+PG) versus mefloquine (MQ)





Statistical method Effect size
9.1 Total failure day 28 PCR-unadjusted 1 158 Risk Ratio (M-H, Fixed, 95% CI) 0.04 [0.00, 0.73]
9.2 Early treatment failure 1 158 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9.3 Adverse events 1 2184 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.75, 1.66]
9.3.1 Serious adverse events 1 182 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9.3.2 Adverse events leading to withdrawal 1 182 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.08]
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Statistical method Effect size
9.3.3 Diarrhoea 1 182 Risk Ratio (M-H, Fixed, 95% CI) 2.50 [0.50, 12.56]
9.3.4 Gastrointestinal and abdominal pains 1 182 Risk Ratio (M-H, Fixed, 95% CI) 5.00 [0.24, 102.72]
9.3.5 Nausea and vomiting 1 182 Risk Ratio (M-H, Fixed, 95% CI) 4.50 [1.00, 20.26]
9.3.6 Appetite disorders 1 182 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.01, 4.11]
9.3.7 Headaches 1 182 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.01, 4.11]
9.3.8 Dizziness 1 182 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.01, 4.11]
9.3.9 Anaemias 1 182 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.23, 1.29]
9.3.10 Abnormal liver function tests 1 182 Risk Ratio (M-H, Fixed, 95% CI) 2.50 [1.02, 6.16]
9.3.11 Disturbances in initiating and main-
taining sleep
1 182 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.73]
9.3.12 Oral soJ tissue signs and symptoms 1 182 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.37, 2.74]
 
 
Analysis 9.1.   Comparison 9: Atovaquone-proguanil (AV+PG) versus






Test for overall effect: Z = 2.18 (P = 0.03)
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Analysis 9.2.   Comparison 9: Atovaquone-proguanil (AV+PG)






Test for overall effect: Not applicable
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Analysis 9.3.   Comparison 9: Atovaquone-proguanil (AV+PG) versus mefloquine (MQ), Outcome 3: Adverse events
Study or Subgroup





Test for overall effect: Not applicable











Test for overall effect: Z = 1.11 (P = 0.27)





Test for overall effect: Z = 1.04 (P = 0.30)









































































































M-H, Fixed, 95% CI
Not estimable
Not estimable
0.33 [0.01 , 8.08]
0.33 [0.01 , 8.08]
2.50 [0.50 , 12.56]
2.50 [0.50 , 12.56]
5.00 [0.24 , 102.72]
5.00 [0.24 , 102.72]
4.50 [1.00 , 20.26]
4.50 [1.00 , 20.26]
0.20 [0.01 , 4.11]
0.20 [0.01 , 4.11]
0.20 [0.01 , 4.11]
0.20 [0.01 , 4.11]
0.20 [0.01 , 4.11]
0.20 [0.01 , 4.11]
Risk Ratio
M-H, Fixed, 95% CI
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Test for overall effect: Z = 1.39 (P = 0.16)





Test for overall effect: Z = 1.99 (P = 0.05)





Test for overall effect: Z = 1.29 (P = 0.20)





Test for overall effect: Z = 0.00 (P = 1.00)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 17.16, df = 10 (P = 0.07); I² = 42%
Test for overall effect: Z = 0.54 (P = 0.59)
























































0.20 [0.01 , 4.11]
0.20 [0.01 , 4.11]
0.54 [0.23 , 1.29]
0.54 [0.23 , 1.29]
2.50 [1.02 , 6.16]
2.50 [1.02 , 6.16]
0.14 [0.01 , 2.73]
0.14 [0.01 , 2.73]
1.00 [0.37 , 2.74]
1.00 [0.37 , 2.74]
1.12 [0.75 , 1.66]
0.01 0.1 1 10 100
Favours AV+PG Favours MQ
Footnotes
(1) Included adverse event 'vomiting' only (not 'nausea').
 
 
Comparison 10.   Atovaquone-proguanil (AV+PG) versus amodiaquine (AQ)





Statistical method Effect size
10.1 Total failure day 28 PCR-un-
adjusted
2 296 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.04, 0.22]
10.2 Early treatment failure 1 170 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.03, 2.66]
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Statistical method Effect size
10.3 Adverse events 2 2860 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.59, 0.96]
10.3.1 Serious adverse events 2 326 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.73]
10.3.2 Adverse events leading to
withdrawal
2 326 Risk Ratio (M-H, Fixed, 95% CI) 3.00 [0.12, 72.77]
10.3.3 Diarrhoea 2 326 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.57, 1.61]
10.3.4 Nausea and vomiting 2 326 Risk Ratio (M-H, Fixed, 95% CI) 1.87 [1.05, 3.33]
10.3.5 Asthenic conditions 2 326 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.02, 0.64]
10.3.6 Respiratory tract infections 1 200 Risk Ratio (M-H, Fixed, 95% CI) 9.00 [0.49, 165.00]
10.3.7 Pruritis 1 126 Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.04, 0.35]
10.3.8 Disturbances in initiating
and maintaining sleep
1 126 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.12, 0.75]
10.3.9 Gastrointestinal and ab-
dominal pains
1 126 Risk Ratio (M-H, Fixed, 95% CI) 2.80 [1.07, 7.31]
10.3.10 Appetite disorders 1 126 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.30, 3.29]
10.3.11 Coughing and associated
symptoms
1 200 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.53, 2.17]
10.3.12 Upper respiratory tract in-
fections
1 200 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.03, 2.20]
10.3.13 Dizziness 1 126 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.08, 0.93]
 
 
Analysis 10.1.   Comparison 10: Atovaquone-proguanil (AV+PG) versus






Heterogeneity: Chi² = 0.01, df = 1 (P = 0.93); I² = 0%
Test for overall effect: Z = 5.32 (P < 0.00001)
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Analysis 10.2.   Comparison 10: Atovaquone-proguanil (AV+PG)






Test for overall effect: Z = 1.10 (P = 0.27)
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Analysis 10.3.   Comparison 10: Atovaquone-proguanil (AV+PG) versus amodiaquine (AQ), Outcome 3: Adverse events
Study or Subgroup






Test for overall effect: Z = 1.29 (P = 0.20)












Heterogeneity: Chi² = 0.58, df = 1 (P = 0.44); I² = 0%
Test for overall effect: Z = 0.16 (P = 0.88)





Heterogeneity: Chi² = 2.29, df = 1 (P = 0.13); I² = 56%






Heterogeneity: Chi² = 0.68, df = 1 (P = 0.41); I² = 0%
Test for overall effect: Z = 2.47 (P = 0.01)
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0.14 [0.01 , 2.73]
Not estimable
0.14 [0.01 , 2.73]
3.00 [0.12 , 72.77]
Not estimable
3.00 [0.12 , 72.77]
0.80 [0.39 , 1.62]
1.20 [0.56 , 2.57]
0.96 [0.57 , 1.61]
1.00 [0.36 , 2.75]
2.63 [1.26 , 5.48]
1.87 [1.05 , 3.33]
0.25 [0.03 , 2.20]
0.06 [0.00 , 1.00]
0.12 [0.02 , 0.64]
9.00 [0.49 , 165.00]
9.00 [0.49 , 165.00]
0.11 [0.04 , 0.35]
0.11 [0.04 , 0.35]
Risk Ratio
M-H, Fixed, 95% CI
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Test for overall effect: Z = 3.78 (P = 0.0002)





Test for overall effect: Z = 2.57 (P = 0.01)











Test for overall effect: Z = 0.00 (P = 1.00)





Test for overall effect: Z = 0.21 (P = 0.84)











Test for overall effect: Z = 2.07 (P = 0.04)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 48.36, df = 15 (P < 0.0001); I² = 69%
Test for overall effect: Z = 2.30 (P = 0.02)







































































0.11 [0.04 , 0.35]
0.29 [0.12 , 0.75]
0.29 [0.12 , 0.75]
2.80 [1.07 , 7.31]
2.80 [1.07 , 7.31]
1.00 [0.30 , 3.29]
1.00 [0.30 , 3.29]
1.08 [0.53 , 2.17]
1.08 [0.53 , 2.17]
0.25 [0.03 , 2.20]
0.25 [0.03 , 2.20]
0.27 [0.08 , 0.93]
0.27 [0.08 , 0.93]
0.76 [0.59 , 0.96]
0.01 0.1 1 10 100
Favours AV+PG Favours AQ
Footnotes
(1) Denominator formed from participants completing treatment.
(2) Denominator formed from participants completing treatment. Includes adverse event 'nausea' only (not 'vomiting').
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Analysis 10.3.   (Continued)
Footnotes
(1) Denominator formed from participants completing treatment.
(2) Denominator formed from participants completing treatment. Includes adverse event 'nausea' only (not 'vomiting').
(3) Originally reported symptom 'weakness'.
(4) Denominator formed from participants completing treatment. Originally reported symptom 'weakness'.
(5) Included adverse event 'common cold' only (not 'respiratory tract infection').
(6) Denominator formed from patients completing treatment.
 
 
Comparison 11.   Atovaquone-proguanil (AV+PG) versus chloroquine (CQ)





Statistical method Effect size
11.1 Total failure day 28 PCR-unad-
justed
1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.06 [0.00, 0.99]
11.2 Early treatment failure 1 27 Risk Ratio (M-H, Fixed, 95% CI) 0.08 [0.01, 1.40]
11.3 Adverse events 1 442 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.36, 0.96]
11.3.1 Serious adverse events 1 34 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
11.3.2 Adverse events leading to with-
drawal
1 34 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [0.09, 49.08]
11.3.3 Gastrointestinal and abdominal
pains
1 34 Risk Ratio (M-H, Fixed, 95% CI) 1.75 [0.39, 7.77]
11.3.4 Nausea and vomiting 1 34 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.44, 3.40]
11.3.5 Dizziness 1 34 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [0.09, 49.08]
11.3.6 Asthenic conditions 1 34 Risk Ratio (M-H, Fixed, 95% CI) 0.06 [0.00, 1.09]
11.3.7 Appetite disorders 1 34 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [0.14, 13.98]
11.3.8 Pruritis 1 34 Risk Ratio (M-H, Fixed, 95% CI) 0.10 [0.01, 1.83]
11.3.9 Cardiac signs and symptoms 1 34 Risk Ratio (M-H, Fixed, 95% CI) 0.10 [0.01, 1.83]
11.3.10 Feelings and sensations 1 34 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.04, 3.50]
11.3.11 Seizures and seizure disorders 1 34 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [0.09, 49.08]
11.3.12 Headaches 1 34 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.05, 0.99]
11.3.13 Disturbances in initiating and
maintaining sleep
1 34 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.20, 5.49]
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Analysis 11.1.   Comparison 11: Atovaquone-proguanil (AV+PG) versus






Test for overall effect: Z = 1.97 (P = 0.05)
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Risk Ratio
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Analysis 11.2.   Comparison 11: Atovaquone-proguanil (AV






Test for overall effect: Z = 1.73 (P = 0.08)
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Analysis 11.3.   Comparison 11: Atovaquone-proguanil (AV+PG) versus chloroquine (CQ), Outcome 3: Adverse events
Study or Subgroup





Test for overall effect: Not applicable





Test for overall effect: Z = 0.48 (P = 0.63)





Test for overall effect: Z = 0.74 (P = 0.46)















































































































M-H, Fixed, 95% CI
Not estimable
Not estimable
2.14 [0.09 , 49.08]
2.14 [0.09 , 49.08]
1.75 [0.39 , 7.77]
1.75 [0.39 , 7.77]
1.23 [0.44 , 3.40]
1.23 [0.44 , 3.40]
2.14 [0.09 , 49.08]
2.14 [0.09 , 49.08]
0.06 [0.00 , 1.09]
0.06 [0.00 , 1.09]
1.40 [0.14 , 13.98]
1.40 [0.14 , 13.98]
0.10 [0.01 , 1.83]
0.10 [0.01 , 1.83]
Risk Ratio
M-H, Fixed, 95% CI
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Test for overall effect: Z = 1.55 (P = 0.12)





Test for overall effect: Z = 1.55 (P = 0.12)





Test for overall effect: Z = 0.89 (P = 0.37)











Test for overall effect: Z = 1.97 (P = 0.05)





Test for overall effect: Z = 0.06 (P = 0.95)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 13.93, df = 11 (P = 0.24); I² = 21%
Test for overall effect: Z = 2.14 (P = 0.03)


































































0.10 [0.01 , 1.83]
0.10 [0.01 , 1.83]
0.10 [0.01 , 1.83]
0.10 [0.01 , 1.83]
0.35 [0.04 , 3.50]
0.35 [0.04 , 3.50]
2.14 [0.09 , 49.08]
2.14 [0.09 , 49.08]
0.23 [0.05 , 0.99]
0.23 [0.05 , 0.99]
1.05 [0.20 , 5.49]
1.05 [0.20 , 5.49]
0.59 [0.36 , 0.96]
0.01 0.1 1 10 100
Favours AV+PG Favours CQ
Footnotes
(1) Denominator for AV+PG formed from addition of 'phase 1' and 'phase 2' trial data.
(2) Denominator for AV+PG formed from addition of 'phase 1' and 'phase 2' trial data. Included reported adverse event 'vomiting' only (not 'nausea').
(3) Denominator for AV+PG formed from addition of 'phase 1' and 'phase 2' trial data. Originally reported symptom 'weakness'.
(4) Denominator for AV+PG formed from addition of 'phase 1' and 'phase 2' trial data. Originally reported symptom 'chills/rigours'.
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Comparison 12.   Atovaquone-proguanil (AV+PG) versus halofantrine (HL)





Statistical method Effect size
12.1 Total failure day 28 PCR-unadjusted 2 205 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.22, 1.88]
12.2 Early treatment failure 2 54 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
12.3 Adverse events 2 3072 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.62, 1.04]
12.3.1 Serious adverse events 2 216 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
12.3.2 Adverse events leading to withdraw-
al
2 216 Risk Ratio (M-H, Fixed, 95% CI) 5.75 [0.71, 46.65]
12.3.3 Headaches 2 216 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.36, 1.50]
12.3.4 Nausea and vomiting 2 216 Risk Ratio (M-H, Fixed, 95% CI) 2.93 [1.36, 6.30]
12.3.5 Gastrointestinal and abdominal
pains
2 216 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.27, 1.08]
12.3.6 Diarrhoea 2 216 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.23, 1.38]
12.3.7 Appetite disorders 1 168 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.10, 1.36]
12.3.8 Disturbances in initiating and main-
taining sleep
2 216 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.22, 1.53]
12.3.9 Rashes, eruptions and exanthems 1 168 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.15, 2.43]
12.3.10 Feelings and sensations 1 168 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.11, 3.89]
12.3.11 Haemorrhages 1 168 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.02, 1.68]
12.3.12 Asthenic conditions 1 168 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.03, 2.19]
12.3.13 Muscle pains 1 168 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.72]
12.3.14 Cardiac signs and symptoms 1 168 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.05, 5.41]
12.3.15 Pruritis 2 216 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.52, 2.90]
12.3.16 Coughing and associated symp-
toms
1 168 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.34, 1.52]
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Analysis 12.1.   Comparison 12: Atovaquone-proguanil (AV+PG) versus







Test for overall effect: Z = 0.81 (P = 0.42)
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Analysis 12.2.   Comparison 12: Atovaquone-proguanil (AV







Test for overall effect: Not applicable
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Analysis 12.3.   Comparison 12: Atovaquone-proguanil (AV+PG) versus halofantrine (HL), Outcome 3: Adverse events
Study or Subgroup






Test for overall effect: Not applicable





Heterogeneity: Chi² = 0.01, df = 1 (P = 0.90); I² = 0%






Heterogeneity: Chi² = 2.84, df = 1 (P = 0.09); I² = 65%
Test for overall effect: Z = 0.84 (P = 0.40)





Heterogeneity: Chi² = 2.58, df = 1 (P = 0.11); I² = 61%
Test for overall effect: Z = 2.75 (P = 0.006)





Heterogeneity: Chi² = 2.54, df = 1 (P = 0.11); I² = 61%






Heterogeneity: Chi² = 0.12, df = 1 (P = 0.73); I² = 0%















































































































5.00 [0.24 , 102.60]
6.46 [0.35 , 118.71]
5.75 [0.71 , 46.65]
0.53 [0.24 , 1.19]
3.68 [0.44 , 30.56]
0.74 [0.36 , 1.50]
1.86 [0.78 , 4.42]
10.12 [1.42 , 72.37]
2.93 [1.36 , 6.30]
0.42 [0.20 , 0.91]
2.76 [0.31 , 24.69]
0.54 [0.27 , 1.08]
0.50 [0.16 , 1.60]
0.69 [0.17 , 2.76]
0.57 [0.23 , 1.38]
0.38 [0.10 , 1.36]
0.38 [0.10 , 1.36]
Risk Ratio
M-H, Fixed, 95% CI
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Test for overall effect: Z = 1.49 (P = 0.14)





Heterogeneity: Chi² = 1.94, df = 1 (P = 0.16); I² = 48%
Test for overall effect: Z = 1.11 (P = 0.27)





Test for overall effect: Z = 0.72 (P = 0.47)























Test for overall effect: Z = 1.29 (P = 0.20)



























































































0.38 [0.10 , 1.36]
0.38 [0.10 , 1.36]
0.29 [0.06 , 1.34]
1.23 [0.31 , 4.90]
0.58 [0.22 , 1.53]
0.60 [0.15 , 2.43]
0.60 [0.15 , 2.43]
0.67 [0.11 , 3.89]
0.67 [0.11 , 3.89]
0.20 [0.02 , 1.68]
0.20 [0.02 , 1.68]
0.25 [0.03 , 2.19]
0.25 [0.03 , 2.19]
0.14 [0.01 , 2.72]
0.14 [0.01 , 2.72]
0.50 [0.05 , 5.41]
0.50 [0.05 , 5.41]
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Analysis 12.3.   (Continued)
Heterogeneity: Not applicable






Heterogeneity: Chi² = 0.29, df = 1 (P = 0.59); I² = 0%
Test for overall effect: Z = 0.46 (P = 0.64)





Test for overall effect: Z = 0.88 (P = 0.38)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 30.01, df = 21 (P = 0.09); I² = 30%
Test for overall effect: Z = 1.68 (P = 0.09)































1.13 [0.46 , 2.78]
2.77 [0.12 , 64.76]
1.23 [0.52 , 2.90]
0.71 [0.34 , 1.52]
0.71 [0.34 , 1.52]
0.80 [0.62 , 1.04]
0.01 0.1 1 10 100
Favours AV+PG Favours HL
Footnotes
(1) Includes adverse event 'vomiting' only (not 'nausea').
(2) Original symptom 'chills/rigours'.
(3) Originally reported as 'epistaxis'.
(4) Original symptom 'weakness'.
 
 
Comparison 13.   Artesunate-atovaquone-proguanil (AS+AV+PG) versus quinine (QN)





Statistical method Effect size
13.1 Total failure day 28 PCR-ad-
justed
1 81 Risk Ratio (M-H, Fixed, 95% CI) 0.05 [0.00, 0.77]
13.2 Total failure day 42 PCR-ad-
justed
1 81 Risk Ratio (M-H, Fixed, 95% CI) 0.08 [0.01, 0.56]
13.3 Total failure day 28 PCR-unad-
justed
1 81 Risk Ratio (M-H, Fixed, 95% CI) 0.03 [0.00, 0.56]
13.4 Total failure day 42 PCR-unad-
justed
1 81 Risk Ratio (M-H, Fixed, 95% CI) 0.06 [0.01, 0.40]
13.5 Early treatment failure 1 81 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.34]
13.6 Adverse events 1 301 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.62, 0.90]
13.6.1 Serious adverse events 1 81 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
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Statistical method Effect size
13.6.2 Adverse events leading to
withdrawal
1 81 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
13.6.3 Auditory nerve disorders 1 58 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.16, 0.60]
13.6.4 Anaemias 1 81 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.91, 1.14]
 
 
Analysis 13.1.   Comparison 13: Artesunate-atovaquone-proguanil (AS+AV






Test for overall effect: Z = 2.15 (P = 0.03)
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Analysis 13.2.   Comparison 13: Artesunate-atovaquone-proguanil (AS+AV






Test for overall effect: Z = 2.54 (P = 0.01)
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Analysis 13.3.   Comparison 13: Artesunate-atovaquone-proguanil (AS+AV






Test for overall effect: Z = 2.37 (P = 0.02)
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Analysis 13.4.   Comparison 13: Artesunate-atovaquone-proguanil (AS+AV






Test for overall effect: Z = 2.87 (P = 0.004)
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Analysis 13.5.   Comparison 13: Artesunate-atovaquone-proguanil (AS






Test for overall effect: Z = 1.00 (P = 0.32)
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Analysis 13.6.   Comparison 13: Artesunate-atovaquone-proguanil
(AS+AV+PG) versus quinine (QN), Outcome 6: Adverse events
Study or Subgroup





Test for overall effect: Not applicable





Test for overall effect: Not applicable











Test for overall effect: Z = 0.38 (P = 0.71)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 36.81, df = 1 (P < 0.00001); I² = 97%
Test for overall effect: Z = 3.12 (P = 0.002)























































0.30 [0.16 , 0.60]
0.30 [0.16 , 0.60]
1.02 [0.91 , 1.14]
1.02 [0.91 , 1.14]
0.75 [0.62 , 0.90]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AS+AV+PG Favours QN
Footnotes
(1) Denominator for specific adverse event reported by study authors.
 
 
Comparison 14.   Chloroquine-atovaquone-proguanil (CQ+AV+PG) versus chloroquine (CQ)





Statistical method Effect size
14.1 Total failure day 28 PCR-unadjust-
ed
1 268 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
14.2 Early treatment failure 1 268 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
14.3 Adverse events 1 640 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.06, 1.35]
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Statistical method Effect size
14.3.1 Serious adverse events 1 320 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.06, 1.35]
14.3.2 Adverse events leading to with-
drawal
1 320 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
 
 
Analysis 14.1.   Comparison 14: Chloroquine-atovaquone-proguanil (CQ+AV






Test for overall effect: Not applicable
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Analysis 14.2.   Comparison 14: Chloroquine-atovaquone-proguanil (CQ






Test for overall effect: Not applicable
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Analysis 14.3.   Comparison 14: Chloroquine-atovaquone-proguanil
(CQ+AV+PG) versus chloroquine (CQ), Outcome 3: Adverse events
Study or Subgroup





Test for overall effect: Z = 1.58 (P = 0.11)









Test for overall effect: Z = 1.58 (P = 0.11)
































M-H, Fixed, 95% CI
0.29 [0.06 , 1.35]
0.29 [0.06 , 1.35]
Not estimable
Not estimable
0.29 [0.06 , 1.35]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours CQ+AV+PG Favours CQ
Footnotes
(1) Includes two deaths in CQ group. Others were 'severe malaria'.
 
 
Comparison 15.   Chloroquine-atovaquone-proguanil (CQ+AV+PG) versus chloroquine-artesunate (CQ+AS)





Statistical method Effect size
15.1 Total failure day 28 PCR-adjust-
ed
1 277 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.01, 8.78]
15.2 Total failure day 28 PCR-unad-
justed
1 277 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.01, 8.78]
15.3 Early treatment failure 1 277 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
15.4 Adverse events 1 640 Risk Ratio (M-H, Fixed, 95% CI) 5.00 [0.24, 103.33]
15.4.1 Serious adverse events 1 320 Risk Ratio (M-H, Fixed, 95% CI) 5.00 [0.24, 103.33]
15.4.2 Adverse events leading to with-
drawal
1 320 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
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Analysis 15.1.   Comparison 15: Chloroquine-atovaquone-proguanil (CQ+AV+PG)






Test for overall effect: Z = 0.63 (P = 0.53)
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Analysis 15.2.   Comparison 15: Chloroquine-atovaquone-proguanil (CQ+AV+PG) versus






Test for overall effect: Z = 0.63 (P = 0.53)
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Analysis 15.3.   Comparison 15: Chloroquine-atovaquone-proguanil (CQ+AV






Test for overall effect: Not applicable
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Analysis 15.4.   Comparison 15: Chloroquine-atovaquone-proguanil (CQ+AV
+PG) versus chloroquine-artesunate (CQ+AS), Outcome 4: Adverse events
Study or Subgroup





Test for overall effect: Z = 1.04 (P = 0.30)









Test for overall effect: Z = 1.04 (P = 0.30)
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Risk Ratio
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Comparison 16.   Chloroquine-atovaquone-proguanil (CQ+AV+PG) versus chloroquine-azithromycin (CQ+AZ)





Statistical method Effect size
16.1 Total failure day 28 PCR-adjusted 1 271 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
16.2 Total failure day 28 PCR-unadjust-
ed
1 271 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.01, 8.41]
16.3 Early treatment failure 1 271 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
16.4 Adverse events 1 640 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.14, 7.01]
16.4.1 Serious adverse events 1 320 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.14, 7.01]
16.4.2 Adverse events leading to with-
drawal
1 320 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
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Analysis 16.1.   Comparison 16: Chloroquine-atovaquone-proguanil (CQ+AV+PG) versus






Test for overall effect: Not applicable
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Analysis 16.2.   Comparison 16: Chloroquine-atovaquone-proguanil (CQ+AV+PG) versus






Test for overall effect: Z = 0.65 (P = 0.51)
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Analysis 16.3.   Comparison 16: Chloroquine-atovaquone-proguanil (CQ+AV+PG)






Test for overall effect: Not applicable
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Analysis 16.4.   Comparison 16: Chloroquine-atovaquone-proguanil (CQ+AV
+PG) versus chloroquine-azithromycin (CQ+AZ), Outcome 4: Adverse events
Study or Subgroup





Test for overall effect: Z = 0.00 (P = 1.00)









Test for overall effect: Z = 0.00 (P = 1.00)
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1.00 [0.14 , 7.01]
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Not estimable
1.00 [0.14 , 7.01]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours CQ+AV+PG Favours CQ+AZ
Footnotes
(1) Includes one death in CQ group. Others were 'severe malaria'.
 
 
Comparison 17.   Adverse events: atovaquone-proguanil (AV+PG) versus all other antimalarials





Statistical method Effect size
17.1 Serious adverse events 15 3222 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.40, 1.28]
17.2 Adverse events leading to withdrawal 14 2969 Risk Ratio (M-H, Fixed, 95% CI) 3.13 [1.29, 7.62]
17.3 Anaemias 2 437 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.28, 1.43]
17.4 Appetite disorders 7 887 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.37, 1.03]
17.5 Asthenic conditions 7 1100 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.39, 0.88]
17.6 Auditory nerve disorders 2 214 Risk Ratio (M-H, Fixed, 95% CI) 0.07 [0.03, 0.18]
17.7 Hypotensive disorders 1 163 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.17, 1.05]
17.8 Breathing abnormalities 1 255 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 1.61]
17.9 Cardiac signs and symptoms 3 365 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.24, 2.29]
17.10 Coughing and associated symptoms 2 368 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.53, 1.48]
17.11 Diarrhoea 11 1733 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.70, 1.35]
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Statistical method Effect size
17.12 Disturbances in initiating and main-
taining sleep
6 765 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.20, 0.64]
17.13 Dizziness 6 871 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.25, 0.57]
17.14 Febrile disorders 2 272 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.47, 2.67]
17.15 Feelings and sensations 4 856 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.39, 1.05]
17.16 Gastrointestinal and abdominal
pains
9 1834 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.76, 1.28]
17.17 Haemorrhages 1 168 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.02, 1.68]
17.18 Headaches 9 1186 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.77, 1.38]
17.19 Hearing problems 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.87]
17.20 Hepatobiliary signs and symptoms 1 163 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.30, 3.28]
17.21 Hypoglycaemic conditions 1 255 Risk Ratio (M-H, Fixed, 95% CI) 4.96 [0.24, 102.33]
17.22 Inner ear signs and symptoms 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 3.03]
17.23 Liver function tests abnormal 1 182 Risk Ratio (M-H, Fixed, 95% CI) 2.50 [1.02, 6.16]
17.24 Lower respiratory tract and lung in-
fections
1 255 Risk Ratio (M-H, Fixed, 95% CI) 2.48 [0.49, 12.55]
17.25 Muscle pains 2 331 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.39, 2.49]
17.26 Nausea and vomiting 12 2196 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.79, 1.23]
17.27 Oral dryness and saliva altered 1 165 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.01, 8.36]
17.28 Oral soJ tissue signs and symptoms 1 182 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.37, 2.74]
17.29 Pruritis 7 858 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.34, 0.87]
17.30 Rashes, eruptions, and exanthems 1 168 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.15, 2.43]
17.31 Rubeola viral infections 1 255 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.11, 3.89]
17.32 Seizures and seizure disorders 2 289 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.11, 6.26]
17.33 Spleen disorders 1 163 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [0.25, 8.64]
17.34 Sepsis, bacteraemia, viraemia, fun-
gaemia
1 255 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.03, 3.14]
17.35 Upper respiratory tract infections 1 200 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.03, 2.20]
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Analysis 17.1.   Comparison 17: Adverse events: atovaquone-proguanil (AV



















Heterogeneity: Chi² = 2.98, df = 5 (P = 0.70); I² = 0%
Test for overall effect: Z = 1.12 (P = 0.26)
















































































M-H, Fixed, 95% CI
Not estimable
0.14 [0.01 , 2.73]
Not estimable
0.99 [0.04 , 23.89]
Not estimable





0.70 [0.35 , 1.41]
Not estimable
Not estimable
0.50 [0.05 , 5.53]
0.99 [0.06 , 15.62]
0.72 [0.40 , 1.28]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
Footnotes
(1) Data from AV+PG versus AS+MQ only.
(2) Data from AV+PG versus AL only.
(3) Data from AV+PG versus CQ only.
(4) Six deaths in AV+PG group, one death in comparator group.
(5) Data from AV+PG versus AS+AV+PG only.
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Analysis 17.2.   Comparison 17: Adverse events: atovaquone-proguanil (AV+PG)















Van Vugt 2002 (4)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 3.25, df = 8 (P = 0.92); I² = 0%
Test for overall effect: Z = 2.52 (P = 0.01)















































































M-H, Fixed, 95% CI
5.00 [0.24 , 102.60]
3.00 [0.12 , 72.77]
6.46 [0.35 , 118.71]
0.99 [0.04 , 23.89]
Not estimable
5.18 [0.25 , 106.33]
Not estimable
2.14 [0.09 , 49.08]
0.33 [0.01 , 8.08]
Not estimable
5.95 [0.73 , 48.75]
Not estimable
3.04 [0.13 , 73.43]
Not estimable
3.13 [1.29 , 7.62]
Risk Ratio
M-H, Fixed, 95% CI
0.001 0.1 1 10 1000
Favour AV+PG Favours other
Footnotes
(1) Data from AV+PG versus AS+MQ only.
(2) Data from AV+PG versus AL only.
(3) Data from AV+PG versus CQ only.
(4) Data from AV+PG versus AM only.
 
 
Analysis 17.3.   Comparison 17: Adverse events: atovaquone-






Heterogeneity: Chi² = 1.03, df = 1 (P = 0.31); I² = 3%
Test for overall effect: Z = 1.11 (P = 0.27)
























M-H, Fixed, 95% CI
0.54 [0.23 , 1.29]
2.98 [0.12 , 72.39]
0.63 [0.28 , 1.43]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
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Analysis 17.4.   Comparison 17: Adverse events: atovaquone-proguanil











Heterogeneity: Chi² = 5.22, df = 6 (P = 0.52); I² = 0%
Test for overall effect: Z = 1.85 (P = 0.06)

















































M-H, Fixed, 95% CI
0.38 [0.10 , 1.36]
0.38 [0.14 , 1.03]
0.33 [0.01 , 7.87]
1.40 [0.14 , 13.98]
0.20 [0.01 , 4.11]
1.48 [0.43 , 5.06]
1.00 [0.30 , 3.29]
0.61 [0.37 , 1.03]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
Footnotes
(1) Data from AP versus QN only.
 
 
Analysis 17.5.   Comparison 17: Adverse events: atovaquone-proguanil











Heterogeneity: Chi² = 14.31, df = 6 (P = 0.03); I² = 58%
Test for overall effect: Z = 2.56 (P = 0.01)

















































M-H, Fixed, 95% CI
0.25 [0.03 , 2.19]
0.25 [0.03 , 2.20]
0.60 [0.28 , 1.29]
0.06 [0.00 , 1.09]
1.44 [0.76 , 2.72]
0.20 [0.01 , 4.09]
0.06 [0.00 , 1.00]
0.58 [0.39 , 0.88]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
Footnotes
(1) Originally reported as 'weakness'.
(2) Originally reported as 'lethargy'.
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Analysis 17.6.   Comparison 17: Adverse events: atovaquone-proguanil (AV






Heterogeneity: Chi² = 2.13, df = 1 (P = 0.14); I² = 53%
Test for overall effect: Z = 5.37 (P < 0.00001)
























M-H, Fixed, 95% CI
0.05 [0.02 , 0.17]
0.33 [0.04 , 3.03]
0.07 [0.03 , 0.18]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
Footnotes
(1) Data from AV+PG versus QN only.
 
 
Analysis 17.7.   Comparison 17: Adverse events: atovaquone-proguanil (AV






Test for overall effect: Z = 1.86 (P = 0.06)



















M-H, Fixed, 95% CI
0.42 [0.17 , 1.05]
0.42 [0.17 , 1.05]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
 
 
Analysis 17.8.   Comparison 17: Adverse events: atovaquone-proguanil (AV






Test for overall effect: Z = 1.63 (P = 0.10)



















M-H, Fixed, 95% CI
0.09 [0.01 , 1.61]
0.09 [0.01 , 1.61]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
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Analysis 17.9.   Comparison 17: Adverse events: atovaquone-proguanil (AV







Heterogeneity: Chi² = 4.12, df = 2 (P = 0.13); I² = 51%
Test for overall effect: Z = 0.52 (P = 0.60)





























M-H, Fixed, 95% CI
0.50 [0.05 , 5.41]
0.10 [0.01 , 1.83]
6.92 [0.36 , 131.79]
0.74 [0.24 , 2.29]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
 
 
Analysis 17.10.   Comparison 17: Adverse events: atovaquone-proguanil (AV+PG)






Heterogeneity: Chi² = 0.61, df = 1 (P = 0.43); I² = 0%
Test for overall effect: Z = 0.45 (P = 0.65)
























M-H, Fixed, 95% CI
0.71 [0.34 , 1.52]
1.08 [0.53 , 2.17]
0.89 [0.53 , 1.48]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
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Analysis 17.11.   Comparison 17: Adverse events: atovaquone-















Heterogeneity: Chi² = 6.42, df = 10 (P = 0.78); I² = 0%
Test for overall effect: Z = 0.18 (P = 0.86)





































































M-H, Fixed, 95% CI
0.50 [0.16 , 1.60]
0.80 [0.39 , 1.62]
0.69 [0.17 , 2.76]
0.86 [0.18 , 4.00]
0.56 [0.20 , 1.58]
3.11 [0.13 , 75.24]
3.00 [0.13 , 70.83]
2.50 [0.50 , 12.56]
1.43 [0.65 , 3.15]
0.99 [0.06 , 15.69]
1.20 [0.56 , 2.57]
0.97 [0.70 , 1.35]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
Footnotes
(1) Data from AV+PG versus AS+MQ only.
(2) Data from AV+PG versus QN only.
 
 
Analysis 17.12.   Comparison 17: Adverse events: atovaquone-proguanil (AV+PG) versus










Heterogeneity: Chi² = 3.65, df = 5 (P = 0.60); I² = 0%
Test for overall effect: Z = 3.46 (P = 0.0005)












































M-H, Fixed, 95% CI
0.29 [0.06 , 1.34]
1.23 [0.31 , 4.90]
0.33 [0.02 , 6.02]
0.34 [0.09 , 1.21]
0.14 [0.01 , 2.73]
0.29 [0.12 , 0.75]
0.36 [0.20 , 0.64]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
Footnotes
(1) Data from AV+PG versus AS+MQ only.
(2) Data from AV+PG versus SP only.
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Analysis 17.13.   Comparison 17: Adverse events: atovaquone-










Heterogeneity: Chi² = 8.10, df = 5 (P = 0.15); I² = 38%
Test for overall effect: Z = 4.72 (P < 0.00001)












































M-H, Fixed, 95% CI
1.07 [0.41 , 2.83]
0.26 [0.14 , 0.48]
0.17 [0.02 , 1.40]
0.20 [0.01 , 4.11]
0.66 [0.25 , 1.77]
0.27 [0.08 , 0.93]
0.38 [0.25 , 0.57]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
Footnotes
(1) Data from AV+PG versus AS+MQ only.
(2) Data from AV+PG versus CQ only.
(3) Denominator formed from patients completing treatment.
 
 
Analysis 17.14.   Comparison 17: Adverse events: atovaquone-proguanil






Heterogeneity: Chi² = 1.69, df = 1 (P = 0.19); I² = 41%
Test for overall effect: Z = 0.27 (P = 0.79)
























M-H, Fixed, 95% CI
2.00 [0.59 , 6.82]
0.60 [0.16 , 2.29]
1.13 [0.47 , 2.67]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
Footnotes
(1) Data only from AV+PG versus AL.
(2) Data only from AV+PG versus QN.
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Analysis 17.15.   Comparison 17: Adverse events: atovaquone-proguanil (AV





Van Vugt 2002 (3)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 2.24, df = 3 (P = 0.52); I² = 0%
Test for overall effect: Z = 1.76 (P = 0.08)


































M-H, Fixed, 95% CI
0.67 [0.11 , 3.89]
3.00 [0.33 , 27.23]
0.35 [0.04 , 3.50]
0.59 [0.34 , 1.02]
0.64 [0.39 , 1.05]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
Footnotes
(1) Data only from AV+PG versus QN.
(2) Data only from AV+PG versus CQ.
(3) Data only from AV+PG versus AS+MQ.
 
 
Analysis 17.16.   Comparison 17: Adverse events: atovaquone-proguanil (AV+PG)













Heterogeneity: Chi² = 16.06, df = 8 (P = 0.04); I² = 50%
Test for overall effect: Z = 0.11 (P = 0.91)



























































M-H, Fixed, 95% CI
0.42 [0.20 , 0.91]
2.76 [0.31 , 24.69]
1.50 [0.28 , 7.96]
1.11 [0.64 , 1.93]
1.13 [0.27 , 4.74]
5.00 [0.24 , 102.72]
1.34 [0.77 , 2.31]
2.80 [1.07 , 7.31]
0.59 [0.33 , 1.04]
0.98 [0.76 , 1.28]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
Footnotes
(1) Data only from AV+PG versus AS+MQ.
(2) Data only from AV+PG versus SP.
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Analysis 17.17.   Comparison 17: Adverse events: atovaquone-proguanil






Test for overall effect: Z = 1.48 (P = 0.14)



















M-H, Fixed, 95% CI
0.20 [0.02 , 1.68]
0.20 [0.02 , 1.68]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
 
 
Analysis 17.18.   Comparison 17: Adverse events: atovaquone-proguanil













Heterogeneity: Chi² = 16.73, df = 8 (P = 0.03); I² = 52%
Test for overall effect: Z = 0.20 (P = 0.84)



























































M-H, Fixed, 95% CI
0.53 [0.24 , 1.19]
3.68 [0.44 , 30.56]
3.00 [1.10 , 8.16]
1.89 [0.90 , 3.97]
0.35 [0.01 , 8.36]
1.20 [0.41 , 3.51]
0.23 [0.05 , 0.99]
0.20 [0.01 , 4.11]
0.95 [0.58 , 1.53]
1.03 [0.77 , 1.38]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
Footnotes
(1) Data only from AV+PG versus AS+MQ.
(2) Data only from AV+PG versus QN.
(3) Data only from AV+PG versus CQ.
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Analysis 17.19.   Comparison 17: Adverse events: atovaquone-proguanil






Test for overall effect: Z = 0.68 (P = 0.50)



















M-H, Fixed, 95% CI
0.33 [0.01 , 7.87]
0.33 [0.01 , 7.87]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
Footnotes
(1) Data only from AV+PG versus QN.
 
 
Analysis 17.20.   Comparison 17: Adverse events: atovaquone-proguanil (AV+PG)






Test for overall effect: Z = 0.02 (P = 0.98)



















M-H, Fixed, 95% CI
0.99 [0.30 , 3.28]
0.99 [0.30 , 3.28]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
 
 
Analysis 17.21.   Comparison 17: Adverse events: atovaquone-proguanil (AV






Test for overall effect: Z = 1.04 (P = 0.30)



















M-H, Fixed, 95% CI
4.96 [0.24 , 102.33]
4.96 [0.24 , 102.33]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
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Analysis 17.22.   Comparison 17: Adverse events: atovaquone-proguanil (AV






Test for overall effect: Z = 0.98 (P = 0.33)



















M-H, Fixed, 95% CI
0.33 [0.04 , 3.03]
0.33 [0.04 , 3.03]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
Footnotes
(1) Data only from AV+PG versus AL.
 
 
Analysis 17.23.   Comparison 17: Adverse events: atovaquone-proguanil (AV






Test for overall effect: Z = 1.99 (P = 0.05)



















M-H, Fixed, 95% CI
2.50 [1.02 , 6.16]
2.50 [1.02 , 6.16]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
 
 
Analysis 17.24.   Comparison 17: Adverse events: atovaquone-proguanil (AV+PG)






Test for overall effect: Z = 1.10 (P = 0.27)



















M-H, Fixed, 95% CI
2.48 [0.49 , 12.55]
2.48 [0.49 , 12.55]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
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Analysis 17.25.   Comparison 17: Adverse events: atovaquone-proguanil






Heterogeneity: Chi² = 2.38, df = 1 (P = 0.12); I² = 58%
Test for overall effect: Z = 0.02 (P = 0.98)
























M-H, Fixed, 95% CI
0.14 [0.01 , 2.72]
1.58 [0.54 , 4.63]
0.99 [0.39 , 2.49]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
 
 
Analysis 17.26.   Comparison 17: Adverse events: atovaquone-proguanil (AV













Van Vugt 2002 (1)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 37.54, df = 11 (P < 0.0001); I² = 71%
Test for overall effect: Z = 0.09 (P = 0.93)










































































M-H, Fixed, 95% CI
1.86 [0.78 , 4.42]
1.00 [0.36 , 2.75]
10.12 [1.42 , 72.37]
1.80 [0.84 , 3.87]
0.55 [0.29 , 1.02]
5.18 [0.25 , 106.33]
0.50 [0.05 , 5.22]
1.23 [0.44 , 3.40]
4.50 [1.00 , 20.26]
0.76 [0.35 , 1.63]
2.63 [1.26 , 5.48]
0.48 [0.32 , 0.73]
0.99 [0.79 , 1.23]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
Footnotes
(1) Data only from AV+PG versus AS+MQ.
(2) Data only from AV+PG versus QN.
(3) Data only from AV+PG versus CQ.
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Analysis 17.27.   Comparison 17: Adverse events: atovaquone-proguanil (AV






Test for overall effect: Z = 0.65 (P = 0.51)



















M-H, Fixed, 95% CI
0.35 [0.01 , 8.36]
0.35 [0.01 , 8.36]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
 
 
Analysis 17.28.   Comparison 17: Adverse events: atovaquone-proguanil (AV+PG)






Test for overall effect: Z = 0.00 (P = 1.00)



















M-H, Fixed, 95% CI
1.00 [0.37 , 2.74]
1.00 [0.37 , 2.74]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
 
 
Analysis 17.29.   Comparison 17: Adverse events: atovaquone-











Heterogeneity: Chi² = 18.29, df = 6 (P = 0.006); I² = 67%
Test for overall effect: Z = 2.54 (P = 0.01)

















































M-H, Fixed, 95% CI
1.13 [0.46 , 2.78]
2.77 [0.12 , 64.76]
1.50 [0.44 , 5.11]
1.04 [0.07 , 16.30]
0.10 [0.01 , 1.83]
3.95 [0.45 , 34.60]
0.11 [0.04 , 0.35]
0.55 [0.34 , 0.87]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
Footnotes
(1) Data only from AV+PG versus CQ.
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Analysis 17.30.   Comparison 17: Adverse events: atovaquone-proguanil (AV+PG)






Test for overall effect: Z = 0.72 (P = 0.47)



















M-H, Fixed, 95% CI
0.60 [0.15 , 2.43]
0.60 [0.15 , 2.43]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
 
 
Analysis 17.31.   Comparison 17: Adverse events: atovaquone-proguanil (AV






Test for overall effect: Z = 0.46 (P = 0.65)



















M-H, Fixed, 95% CI
0.66 [0.11 , 3.89]
0.66 [0.11 , 3.89]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
 
 
Analysis 17.32.   Comparison 17: Adverse events: atovaquone-proguanil (AV






Heterogeneity: Chi² = 0.67, df = 1 (P = 0.41); I² = 0%
Test for overall effect: Z = 0.17 (P = 0.86)
























M-H, Fixed, 95% CI
2.14 [0.09 , 49.08]
0.33 [0.01 , 8.04]
0.84 [0.11 , 6.26]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
Footnotes
(1) Data only from AV+PG versus SP.
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Analysis 17.33.   Comparison 17: Adverse events: atovaquone-proguanil






Test for overall effect: Z = 0.44 (P = 0.66)



















M-H, Fixed, 95% CI
1.48 [0.25 , 8.64]
1.48 [0.25 , 8.64]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
 
 
Analysis 17.34.   Comparison 17: Adverse events: atovaquone-proguanil (AV+PG)






Test for overall effect: Z = 0.96 (P = 0.34)



















M-H, Fixed, 95% CI
0.33 [0.03 , 3.14]
0.33 [0.03 , 3.14]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
 
 
Analysis 17.35.   Comparison 17: Adverse events: atovaquone-proguanil (AV






Test for overall effect: Z = 1.25 (P = 0.21)



















M-H, Fixed, 95% CI
0.25 [0.03 , 2.20]
0.25 [0.03 , 2.20]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favour AV+PG Favours other
 
 
Comparison 18.   Supplementary: atovaquone-proguanil (AV+PG) versus WHO-recommended artemisinin-based
combination therapy (ACT)





Statistical method Effect size
18.1 Total failure day 28 PCR-adjusted 2 192 Risk Ratio (M-H, Fixed, 95% CI) 3.56 [0.89, 14.19]
18.2 Total failure day 28 PCR-unadjusted 1 132 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.49, 2.91]
18.3 Total failure day 42 PCR-adjusted 2 1271 Risk Ratio (M-H, Fixed, 95% CI) 3.02 [1.17, 7.78]
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Statistical method Effect size
18.4 Total failure day 42 PCR-unadjusted 2 1123 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.54, 1.38]
 
 
Analysis 18.1.   Comparison 18: Supplementary: atovaquone-proguanil (AV+PG) versus WHO-






Heterogeneity: Chi² = 0.07, df = 1 (P = 0.79); I² = 0%
Test for overall effect: Z = 1.80 (P = 0.07)
























M-H, Fixed, 95% CI
5.00 [0.25 , 99.95]
3.19 [0.67 , 15.22]
3.56 [0.89 , 14.19]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+PG Favours ACT
Footnotes
(1) Study described 'early treatment failures' included in total treatment failures as PCR was performed at day 7 and day 28.
 
 
Analysis 18.2.   Comparison 18: Supplementary: atovaquone-proguanil (AV+PG) versus WHO-recommended






Test for overall effect: Z = 0.39 (P = 0.69)



















M-H, Fixed, 95% CI
1.20 [0.49 , 2.91]
1.20 [0.49 , 2.91]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+PG Favours ACT
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Analysis 18.3.   Comparison 18: Supplementary: atovaquone-proguanil (AV+PG) versus WHO-
recommended artemisinin-based combination therapy (ACT), Outcome 3: Total failure day 42 PCR-adjusted
Study or Subgroup
Carrasquilla 2012
Van Vugt 2002 (1)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 2.28 (P = 0.02)
























M-H, Fixed, 95% CI
3.00 [0.19 , 47.12]
3.02 [1.10 , 8.24]
3.02 [1.17 , 7.78]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+PG Favours ACT
Footnotes
(1) Authors reported missing data as treatment failures; denominator was number randomized, not evaluable population.
 
 
Analysis 18.4.   Comparison 18: Supplementary: atovaquone-proguanil (AV+PG) versus WHO-recommended






Heterogeneity: Chi² = 1.40, df = 1 (P = 0.24); I² = 29%
Test for overall effect: Z = 0.61 (P = 0.54)
























M-H, Fixed, 95% CI
5.00 [0.25 , 99.95]
0.80 [0.50 , 1.30]
0.86 [0.54 , 1.38]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours AV+PG Favours ACT
 
 
A D D I T I O N A L   T A B L E S
 




Exclusions after enrolment Excludedc Excluded Excluded Excluded









As 'Primary analysis' except missing or indeter-
minate PCR














Included Included as fail-
ures
Included
Table 1.   Sensitivity analysis 
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Sensitivity analy-
sis 4g




Included Included as suc-
cesses
Included
Table 1.   Sensitivity analysis  (Continued)
aNote: participants who did not satisfy the inclusion criteria aJer randomization were removed from all calculations.
bPCR: polymerase chain reaction.
c'Excluded' means removed from the calculation.
dTo reclassify all indeterminate or missing PCR results as treatment failures in the PCR-adjusted analysis.
eTo reclassify all PCR-confirmed new infections as treatment successes in the PCR-adjusted analysis. (This analysis may overestimate
eNicacy as PCR is not wholly reliable and some recrudescences may be falsely classified as new infections. Also some participants may
have gone on to develop a recrudescence aJer the new infection.)
fTo reclassify all exclusions aJer enrolment (losses to follow-up, withdrawn consent, other antimalarial use, or failure to complete
treatment) as treatment failures. For PCR-unadjusted total failure this represents a true worst-case scenario.
gTo reclassify all exclusions aJer enrolment (losses to follow-up, withdrawn consent, other antimalarial use, or failure to complete
treatment) as treatment successes.
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  WHO-recommended artemisinin-based combination therapy Other antimalarials






Anabwani 1999 √ — — — — — HL
Borrmann 2003 √ — — — — — AQ
Bouchaud 2000 √ — — — — — HL
Carrasquilla 2012 √ √ — √ — — —
De Alencar 1997 √ — — — — QN
+TET
—
Giao 2004 √ — — — — CV8 —
Gurkov 2008 √ √ — — — — QN
Llanos-Cuentas 2001 √ — — — — — CQ, SP
Looareesuwan 1999 √ — — — — — MQ
Mulenga 1999 √ — — — — — SP
Mulenga 2006 √ — — — — — SP
RadloN 1996 √ — — — — — AQ
Tahar 2014 √ — √ — √ — —
Van Vugt 2002 √ — — √ √ — —
Wojnarski 2019 √ — — — √ — —
McGready 2005 — — — — √ — QN
Laufer 2012 — — — — — CQ
+AS,
CQ



























































































































































































Total number 15 2 1 2 4 3 11
Table 2.   Comparison of Interventions  (Continued)
AL: artemether-lumefantrine; AQ: amodiaquine; AS+AQ: artesunate-amodiaquine; AS+AV+PG: artesunate-atovaquone-proguanil; AS+MQ: artesunate-mefloquine; AV
+PG: atovaquone-proguanil; CQ: chloroquine; CQ+AS: chloroquine-artesunate; CQ+AV+PG: chloroquine-atovaquone-proguanil; CQ+AZ: chloroquine-azithromycin; CV8:


















Anabwani 1999 √ √ √ √ — — —
Borrmann 2003 √ √ √ √ — — —
Bouchaud 2000 √ √ √ √ — — —
Carrasquilla 2012 √ √ — — — √ —
De Alencar 1997 √ √ √ √ — — —
Giao 2004 √ √ √ √ — — —
Gurkov 2008 √ √ — — — √ —
Laufer 2012 √ √ — — — — √
Llanos-Cuentas 2001 √ √ √ √ — — —
Looareesuwan 1999 √ √ √ √ — — —
McGready 2005 √ √ √ √ √ — √
Mulenga 1999 √ √ √ √ — — —






















































































































































































Mulenga 2006 √ √ — √ — — —
RadloN 1996 √ √ √ √ — — —
Tahar 2014 √ √ √ √ — — √
Van Vugt 2002 √ √ √ √ √ — —
Wojnarski 2019 √ √ √ √ √ — √
Total number making comparison 17 17 13 14 3 2 4




































































Cochrane Database of Systematic Reviews
 






Anabwani 1999 1994 Africa 6% 10%
Borrmann 2003 1999–2000 Africa 1–4% 4–47%
Bouchaud 2000 1994–1995 Returning travellers 0% 0%
Carrasquilla 2012 2007–2008 South America 2% 1–2%
De Alencar 1997 1995–1996 South America 0–1% 0%
Giao 2004 2001–2002 Asia 0–6% 0–5%
Gurkov 2008 2006 Africa 0–7% 0–23%
Laufer 2012 2007–2009 Africa 0% (+CQ) 0–1%
Llanos-Cuentas 2001 1995–1996 South America 0% 0–54%
Looareesuwan 1999 1993–1994 Asia 0% 0–14%
McGready 2005 2001–2003 Asia 0–3% (+AS) 0–45%
Mulenga 1999 1993–1994 Africa 0% 1%
Mulenga 2006 2000–2002 Africa 0–5% 1–22%
RadloN 1996 1994–1995 Africa 2% 19%
Tahar 2014 2008–2009 Africa 2–15% 0–12%
Van Vugt 2002 1998–2000 Asia 3–5% 1–7%
Wojnarski 2019 2014–2015 Asia 0–9% 0–8%
Table 4.   Trial dates, global region, and drug failure rates 
Failure rates presented to the nearest percentage. Shows range of failure rates reported at diNerent outcome time points including both
PCR-adjusted and PCR-unadjusted data.
AV+PG: atovaquone-proguanil; PCR: polymerase chain reaction.
 
 
Total treatment failure day 28 PCR-adjustedStudy
Events Total
Observed rate
Gurkov 2008 2 30 6.67%
Tahar 2014 6 64 9.38%
Mulenga 2006 0 97 0%
Table 5.   Crude PCR-adjusted failures for atovaquone-proguanil 
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Wojnarski 2019 1 93 1.08%
Total treatment failure day 42 PCR-adjustedStudy
Events Total
Observed rate
Carrasquilla 2012 1 152 0.66%
Van Vugt 2002 15 530 2.83%
Wojnarski 2019 9 98 9.18%
Table 5.   Crude PCR-adjusted failures for atovaquone-proguanil  (Continued)
PCR: polymerase chain reaction.
 
 
Comparator Studies Efficacy findings Adverse events
CV8 Giao 2004 Little or no difference between AV+PG and CV8
in PCR-unadjusted treatment failures day 28
(Analysis 5.1; Analysis 5.2).
Few adverse events reported.
QN+TET De Alencar 1997 1 PCR-unadjusted treatment failure at day 28 re-
ported (Analysis 6.1).





3 RCTs contributed data to analysis.
Little or no difference for PCR-adjusted treat-
ment failures at day 28 (Analysis 7.1).
Greater PCR-unadjusted treatment failures at
day 28 for SP (Analysis 7.2).
Large numbers of adverse events reported,
but little or no difference between AV+PG
and SP.
QN Gurkov 2008 Study reported PCR adjusted data at day 28, and
unadjusted data at day 42.
Little or no difference for PCR-adjusted treat-
ment failures at day 28 (Analysis 8.1) or PCR-un-
adjusted treatment failures at day 42 (Analysis
8.2).
Small numbers of adverse events reported.




Fewer PCR-unadjusted treatment failures at day
28 for AV+PG compared to MQ (Analysis 9.1).
Several adverse events reported.
Both nausea and vomiting symptoms and
abnormal liver function tests more fre-
quent with AV+PG versus MQ (Analysis 9.3).
AQ RadloN 1996;
Borrmann 2003
2 RCTs contributed data to analysis.
Fewer failures PCR-unadjusted failures at day 28
for AV+PG compared to AQ (Analysis 10.1).
Several adverse events reported. Asthenic
conditions, pruritis, sleep disturbance, and
dizziness more common in the AQ group.




1 small RCT (27 participants). Fewer PCR-unad-
justed failures at day 28 for AV-PG compared to
CQ (Analysis 11.1).
Several adverse events reported with
little or no difference between groups.
Headaches more common in CQ group.
Table 6.   Studies comparing atovaquone-proguanil to other combinations or to monotherapy 
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HL Anabwani 1999;
Bouchaud 2000
2 RCTs contributed data to analysis. Little or no
difference between AV+PG and HL in PCR-unad-
justed treatment failures day 28 (Analysis 12.1).
Nausea and vomiting seen more frequently
with AV+PG compared to HL.
Table 6.   Studies comparing atovaquone-proguanil to other combinations or to monotherapy  (Continued)
AQ: amodiaquine; CQ: chloroquine; CV8: dihydroartemisinin-piperaquine-trimethoprim-primaquine; HL: halofantrine; MQ: mefloquine;
QN: quinine; QN+TET: quinine-tetracycline; RCT: randomized controlled trial; SP: sulfadoxine-pyrimethamine.
 
 
A P P E N D I C E S










2 proguanil proguanil Exp MALARIA Exp MALARIA proguanil
3 Malarone Malarone 1 or 2 1 or 2 ato-
vaquone
4 malaria malaria atovaquone atovaquone Malarone
5 — — proguanil proguanil —
6 — — Atovaquone-proguanil Atovaquone-proguanil —
7 — — chloriguane chloriguane —
8 — — Chlorguanid* cycloguanil —
9 — — cycloguanil 7 or 8 —
10 — — 7 or 8 or 9 5 or 9 —
11 — — 5 or 10 4 and 10 —
12 — — 4 and 10 6 or 11 —
13 — — 6 or 12 Malarone —
14 — — Malarone 12 or 13 —
15 — — 13 or 14 3 and 14 —
16 — — 3 and 15 — —
17 — — — — —
 
 
aCochrane Infectious Diseases Group Specialized Register.
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bSearch terms used in combination with the search strategy for retrieving trials developed by Cochrane; upper case: MeSH or EMTREE










AQ Amodiaquine AL Artemether-lumefantrine
AM Artemether AS+AQ Artesunate-amodiaquine
ART Artemisinin AS+AV+PG Artesunate-atovaquone-proguanil
AS Artesunate AS+MQ Artesunate-mefloquine
AV Atovaquone AV+PG Atovaquone-proguanil
AZ Azithromycin CV8 Dihydroartemisinin-piperaquine-trimethoprim-pri-
maquine
CL Clindamycin SP Sulfadoxine-Pyrimethamine
CQ Chloroquine QN+TET Quinine-Tetracycline
DHA Dihydroartemisinin CQ+AV+PG Chloroquine-Atovaquone-Proguanil
HL Halofantrine CQ+AS Chloroquine-Artesunate













ACPR: clinical and parasitological response
ACT: artemisinin-based combination therapy
CENTRAL: Cochrane Central Register of Controlled Trials
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CI: confidence interval
CIDG: Cochrane Infectious Diseases Group
GRADE: Grading of Recommendations, Assessment, Development and Evaluation
MedDRA: Medical Dictionary for Regulatory Activities
P falciparum: Plasmodium falciparum
PCR: polymerase chain reaction
PCV: packed cell volume
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
RCT: randomized controlled trial
RR: risk ratio
WHO: World Health Organization
Appendix 3. Prespecified changes for review update 2021
 
Protocol section Refreshed protocol
Background We updated the title to reflect that the review pertains to Plasmodium falciparum malaria, and fol-
lows Cochrane title conventions.
We updated information in the background to follow the advised Cochrane/MECIR subheading
structure.
We updated the background to reflect the current global policy setting on malaria.
The main review question has acquired a new relevance in the context of emerging artemisinin re-
sistance; we reflected this in the updated protocol.
Research question The existing PICO (population, intervention, comparison, outcome) remained relevant.
We updated the protocol to incorporate WHO standards on reporting of malaria trials. These are in
harmony with other Cochrane Reviews of malaria.
Our protocol did not incorporate participant-reported outcomes. In accordance with Cochrane
guidelines, we restricted the number of primary and secondary outcomes.
The inclusion criteria remain limited to randomized controlled trials.
Methods We updated the description of the 'Risk of bias' tool.
We added a plan to summarize the evidence using the GRADE approach.
 
 
This table was approved by the Cochrane Infectious Diseases Group editorial team on 27 April 2018.
W H A T ' S   N E W
 
Date Event Description
14 January 2021 New citation required and conclusions
have changed
A new author team (Andrew Blanshard and Paul Hine) prepared
this review. We have rewritten the protocol, updated the back-
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Date Event Description
ground to reflect changes in the field, updated the outcomes of
the review, and used newer Cochrane methodology.
14 January 2021 New search has been performed We aligned the outcomes with the emerging core outcome set
used by the Cochrane Infectious Diseases Group. This led us to
remove the following secondary outcomes from the original pro-
tocol.
• Treatment failure by day 14: we replaced this with early treat-
ment failure.
• Parasite clearance time: we omitted this as there is commonly
heterogeneity in measures of parasite clearance time between
studies, as encountered in previous Cochrane Reviews (see Esu
2014). The preferred measure would be parasite clearance rate
using the WWARN calculator (Flegg 2011), but we did not in-
clude as the frequent sampling required may be too demand-
ing for trials in resource-limited settings.
• Fever clearance time: we omitted this as there was overlap with
early treatment failure.
• Progression to severe malaria: we omitted this as there was
overlap with early treatment failure and treatment failure at
day 28 and day 42.
An updated protocol was approved by the CIDG editorial team
on 27 April 2018, and the changes are described in Appendix 3. In
a change to the protocol, we focused comparisons on WHO-ap-
proved ACT, and presented the other comparisons in narrative
format as we consider this will be of more relevance to current
clinical practice.
 
H I S T O R Y
Protocol first published: Issue 4, 2003
Review first published: Issue 4, 2005
 
Date Event Description
5 August 2008 Amended Converted to new review format with minor editing.
 
C O N T R I B U T I O N S   O F   A U T H O R S
PH and AB updated the protocol of this review in March 2018. They both extracted data from all studies, completed the 'risk of bias'
assessments, results, summary of findings, and analysis.
Both review authors read and approved the final manuscript.
D E C L A R A T I O N S   O F   I N T E R E S T
AB has no known conflicts of interest. He is a doctor working full time within the UK National Health Service (NHS).
PH was previously employed full-time by the Cochrane Infectious Diseases Group (CIDG), is a CIDG Editor, and currently works full-time
within the UK NHS. He received a Registration Scholarship to attend the 23rd Annual British HIV Association Conference 2017 from ViiV
healthcare. ViiV had no involvement in the selection of recipients of the scholarship. In 2018, he attended a CPD certified clinical research
training programme organized and funded by Gilead Sciences Europe Ltd. To the best of his knowledge, neither financial nor non-financial
conflicts of interests have influenced the current submitted work.
Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria (Review)










Cochrane Database of Systematic Reviews
S O U R C E S   O F   S U P P O R T
Internal sources
• Liverpool School of Tropical Medicine, UK
External sources
• Foreign, Commonwealth and Development ONice (FCDO), UK
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
An updated protocol was approved by the CIDG editorial team on 27 April 2018, and the changes are described in Appendix 3. In a change
to the protocol, we focused comparisons on WHO-approved ACT, and presented the other comparisons in narrative format as we consider
this will be of more relevance to current clinical practice.
We intended to explore heterogeneity using subgroup analysis, but there were too few trials in each comparison to yield meaningful results.
We intended to conduct a sensitivity analysis adding excluded groups back into the analysis in using stepwise methods. Given the small
number of trials included for each comparison, we did not pursue this, but the planned analysis is presented in Table 1 for reference.
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